UK Dementias Platform

Lead Research Organisation: University of Oxford
Department Name: Psychiatry

Abstract

The UK Dementias Platform (UKDP) is a radically new approach to dementias research, bringing together data from around 2,000,000 study participants from 22 cohorts to try and discover the causes of dementia and to find out ways of slowing it down. The platform has been funded to the level of £4.5M and invited to apply for a further £7.5M.

To achieve our goals of discovering the causes of dementia and finding out ways to slow it down, we will analyse data collected over many decades from throughout the UK to identify targets for drugs studies.

We will also enrich strategically selected cohorts to provide resources for dementias research in general. This will involve finding out how the early dementia processes begin, how our genes affect our risk of dementia and where our body goes wrong in maintaining and repairing itself.

There are many practical challenges involved in doing this work including knowing how to assess dementia in large studies where having everyone examined by a doctor would be prohibitively expensive. Another challenge is how to measure cognitive decline in the population as when people begin to decline they are frequently less motivated to do cognitive tests.

There are also important ethical issues surrounding this work and we have specific projects looking at ethical legal and social issues surrounding taking part in detailed measurement studies as well as in considering brain donation.

To help make an impact as soon as possible, we will work closely with industry partners who are best placed to turn basic scientific knowledge into effective therapies.

Even if we cannot cure dementia in the short term, it would count as a success if we found ways of slowing it down so that nobody need lose their dignity as they grew older.

Technical Summary

The UK Dementias Platform (UKDP) is a radically new approach to dementias research, providing a highly efficient and cost-effective translation pipeline from basic discovery through to early phase trials (Fig 1). By combining the analytic and statistical power of >20 clinical and population cohorts representing 2M participants and creating a large readiness cohort, UKDP will create an optimal environment for basic discovery activities relevant to the clinical progression and human impact of dementia. Although UKDP is intended as a strategic and sustainable resource generating increasing scientific benefit over time, it will also deliver short and medium term benefits through the analysis of existing data, the enrichment of strategically selected cohorts, developing new ways of working with industry, and generating interest and further funding for dementias research generally.

A single portal informatics hub (funded in stage 1) will be used for integrating data from participating cohorts and triangulating evidence between cohorts. The stage 2 proposal focuses on providing strategic resources for EM by enriching strategically selected cohorts, addressing key methodological issues and pump-priming a programme of EM studies.

Further development of the platform is anticipated as the opportunities it provides are more widely understood. For example, predicated on the ability of the platform's ability to provide accurately risk stratification, MRC and NIHR have recently funded a deep and frequent Phenotyping (DFP) feasibility study with a view to providing a further £5M for the full study. The DFP project may be considered a stage 3 development of UKDP and is an example of how UKDP can be used to leverage further resource for dementias research.

Planned Impact

The platform will use several vehicles to deliver impact.

These were described in stage 1.

In summary:

For the academic community, in addition to the proposals mad in stage 1, we will develop a network of partnerships and operate a system of working groups to actively consult the UK academic community and world experts on the direction, technologies and collaborations of the platform. Our aim is to 1) base the science of the platform on the best information available, 2) create momentum in dementias research by being inclusive of, and synergistic with, other initiatives.

For industry, partnership discussions are already underway with exchanges of ides, interests and needs between academic and industry stakeholders. Industry have identified their need for access to conversion (early MVI to dementia cohorts and for experimental medicine studies to conform to regulatory requirements.

We remain committed to raising the profile of contemporary debate about dementia and its treatment. We wish to encourage a culture of commitment to solving this problem. By increasing awareness at all levels of society we intend to leverage resources for the platform and for dementia research in general, to increase awareness of the need for earlier interventions and better targeted treatment in general by health service providers and the public alike.

Engagement with the general public and with patients and carers is a very important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma in society and the research culture in the NHS in relation to dementia and older people. In addition to using the platform web-site to communicate to the general public, we will also liaise with charities and advocate groups such as Age UK and the Alzheimer's Society to promote our work and findings and to engage them in shaping the work programme.

In addition we will have a dedicated free-phone number available 6 days a week and a communications officer at 50% FTE over 5 years whose responsibility is to develop and implement a communications and public engagement strategy.

Organisations

Publications

10 25 50

publication icon
Ahmad S (2018) Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. in Alzheimer's & dementia : the journal of the Alzheimer's Association

publication icon
Alex B (2019) Text mining brain imaging reports. in Journal of biomedical semantics

 
Title 3 video interviews with research participant, senior industry scientist and senior academic researcher 
Description Three video interviews to bring the importance of dementia research and the DPUK project to life for our general public audience through our social media channels (YouTube and Twitter). 
Type Of Art Film/Video/Animation 
Year Produced 2017 
Impact Increased awareness of DPUK and the need for investment new ways of working in dementia research. 
URL https://www.youtube.com/watch?v=FYlkBpb_D_A
 
Title Animation - 'Introducing Dementias Platform UK' 
Description This animation has been used on the homepage and About pages of the DPUK website to give the general public an easily accessible overview of Dementias Platform UK aims and work. 
Type Of Art Film/Video/Animation 
Year Produced 2017 
Impact Our audience research has shown that the general public find this animation useful in understanding the complex DPUK project. 
URL https://www.dementiasplatform.uk/about
 
Title Cognitive resources leaflet and webpage 
Description A promotional leaflet designed to direct the target audience of dementia researchers to an information hub with guides and resources for using cognitive data 
Type Of Art Artefact (including digital) 
Year Produced 2019 
Impact The web pages have received 2,532 visits 
URL https://www.dementiasplatform.uk/cognition
 
Title DPUK 5 year celebratory event video 
Description A video round-up of the celebratory event held in September 2019 shared with those invited to attend the event and on social media 
Type Of Art Film/Video/Animation 
Year Produced 2019 
Impact The video received 102 views on youtube and social media clips of the video uploaded to twitter were viewed 1,567times. 
URL https://youtu.be/Q9QIhA9Fo8A
 
Title DPUK Linked in profile 
Description To generate greater engagement with industry DPUK is now as an active Linked In page with regular news updates 
Type Of Art Artefact (including digital) 
Year Produced 2019 
Impact Following our drive for greater engagement with researchers in industry with an interest in data and dementia we now regularly post updates. We have an engagment rate of 9.39% and have grown followers by 44% in six months. 
URL https://www.linkedin.com/company/18392913
 
Title DPUK newsletter (produced 3 times a year) 
Description The DPUK newsletter is sent three times a year to researchers, related organisations in the dementia research sector, industry companies working in dementia research and development and major funders in the dementia research sector. It features updates on the developments and opportunities in DPUK. 
Type Of Art Artefact (including digital) 
Year Produced 2017 
Impact Increased awareness of DPUK resources amongst key audience groups: scientists; funders and industry. 
 
Title Data Portal communications pack 
Description This pack was produced an distributed to DPUK's 16 partner organisations (10 universities and 6 pharmaceutical companies) to support the promotion of the Data Portal campaign. 
Type Of Art Artefact (including digital) 
Year Produced 2018 
Impact 150% increase in traffic driven to DPUK website; increased awareness amongst the dementia research community of DPUK's tools, resources, training and funding opportunities for researchers. 
 
Title Data Portal press release 
Description Press release to all major science publications and science desks of print media at the launch of the DPUK Data Portal. 
Type Of Art Artefact (including digital) 
Year Produced 2017 
Impact None we are aware of. 
 
Title Data Portal resource hub 
Description Developing a hub of resources and guides that support Data Portal users from applying to analysing data. This resource hub includes fact sheets on using big data, applying for Data Portal data and learning about using the virtual desktop with a synthetic data set. Additionally there are two explainer videos describing how to identify the data you need and analyse it within the virtual desktop 
Type Of Art Artefact (including digital) 
Year Produced 2019 
Impact The resource page has been visited X times, videos have been viewed X times and the factsheets have been visited 3,521 times 
URL https://www.dementiasplatform.uk/for-researchers/data-portal-getting-started-with-cohort-data
 
Title Datathon Leaflet 
Description A highly visual printed promotional postcard for distribution to target audiences at talke, conferences and events to drive recruitment to datathon events in Swansea, Exeter, UEA and Ulster universities. 
Type Of Art Artefact (including digital) 
Year Produced 2019 
Impact The total number of visitors to the datathon recruitment pages was 828 
 
Title Datathon recruitment web pages 
Description The datathon pages promote and provide guidance for those interested in joining a datathon workshop. All other datathon communication - leaflets, social media,enews - direct the audience to this hub. 
Type Of Art Artefact (including digital) 
Year Produced 2019 
Impact Over the course of the year the datathon web hub received 6,728 page views. Social media posts reached 107,073 impressions and resulted in 3,108 engagements Each datathon was fully booked - with a total of 92 attending workshop events 
URL https://www.dementiasplatform.uk/for-researchers/data-portal-getting-started-with-cohort-data/datath...
 
Title Great Minds animated graphic 
Description An animated graphic explaining the value of cohort participants to dementia clinical studies and trials. 
Type Of Art Film/Video/Animation 
Year Produced 2019 
Impact Helped support the recruitment of 45 people to the Great Minds clinical studies register pilot, showing their interest in taking part in future dementia research. 
URL https://www.youtube.com/watch?v=TTLyYF021uA
 
Title Information sheet 
Description This information sheet was sent out to our 16 partners (10 partner universities and 6 partner pharmaceutical companies) for inclusion, alongside a news feature, in internal newsletters. 
Type Of Art Artefact (including digital) 
Year Produced 2018 
Impact Increased engagement from research scientists based at universities and in industry with DPUK's resources on the DPUK website and DPUK Data Portal website. Attendance at DPUK training webinars and expressions of interest/applications for DPUK's 'Discovery Award' funding opportunities for researchers. 
 
Title Leaflet 
Description Leaflet produced for distribution at the Alzheimer's Research UK conference. 
Type Of Art Artefact (including digital) 
Year Produced 2017 
Impact The leaflet helped to raise awareness amongst the community of dementia researchers of DPUK's free tools and data resources for researchers. 
 
Title Leaflet - 2017 
Description Leaflet produced for distribution at the Alzheimer's Association International Conference, attended by over 6000 researchers. 
Type Of Art Artefact (including digital) 
Year Produced 2017 
Impact Increased awareness amongst the dementia research community worldwide about DPUK's tools and data resources for researchers. 
 
Title Leaflet - 2018 
Description Leaflet included in the Alzheimer's Research UK 2018 conference delegate pack (going to 650 people). 
Type Of Art Artefact (including digital) 
Year Produced 2018 
Impact At the time of writing the conference itself has not yet taken place. 
 
Title MEG & ME 
Description With ISSF funding, out team held a series of public open evenings to discuss research of interest to the public, to define a sho set of questions and design the experiments to answer them, and then carry it out using MEG. The project was filmed, and presented at a final public discussion meeting at the Cambridge Science Festival 
Type Of Art Film/Video/Animation 
Year Produced 2015 
Impact The project clearly caught he public's imagination, and over 100 members of the public took part across the weeks. https://vimeo.com/116423919 presents a final summary video 
URL https://vimeo.com/116423919
 
Title Magazine article 
Description John Gallacher was interviewed for this feature in Optima magazine (a lifestyle magazine) about the importance of participation in health research. 
Type Of Art Artefact (including digital) 
Year Produced 2017 
Impact Feature in Optima magazine. 
URL http://www.optimamagazine.co.uk/read/style/health/1628-banking-time
 
Title Miscellaneous branded images for DPUK and Dataportal 
Description Various images, such as the Dataportal background image, genetic computer background and DPUK twitter badge for email signatures. 
Type Of Art Image 
Year Produced 2019 
Impact - Researchers utilising the Data portal virtual desktop will now have no doubt what they are using - Any press conducted at events such as Datathons, will now capture the DPUK logo on the background of the virtual desktop, instead of the standard windows background. - Traffic is now drawn to the DPUK twitter page each time DPUK staff sends an email. 
 
Title Misplaced in Space (September 2017) 
Description A collaboration with University of East Anglia, to portray the impact of Dementia 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2017 
Impact A film of the exhibition is available; 
URL https://vimeo.com/229381641
 
Title New blog space on DPUK website 
Description Creating a space for new and relevant content for the target audience where DPUK researchers and partners can outline their research, achievements or experience. 
Type Of Art Creative Writing 
Year Produced 2019 
Impact New blogs are key content on twitter and LinkedIn for engagement. The are regularly shared on social media. The blog section of the website has been viewed 3,461 times in a year with an average read time of over a minute 
URL https://www.dementiasplatform.uk/blog
 
Title Social media videos 
Description Event-based video interviews for release on social media. 
Type Of Art Film/Video/Animation 
Year Produced 2019 
Impact Ove the past 12 months we have created 45 social media interview videos with a range of DPUK researchers, external ECRs, Senior researchers and Professors and Charity managers. these have been viewed 23,085 times in the past year. Many of these can be seen on our Youtube channel 
URL https://www.youtube.com/channel/UC9OKgZG5Dq0RheCDV3upakw/videos
 
Title Study recruitement web page 
Description A public news and information page designed to allow the public to sign-up to be considered as a participant of a small imaging study. This page was part of a local and media campaign calling for volunteers 
Type Of Art Artefact (including digital) 
Year Produced 2020 
Impact 27 people registered their interest in participating. 
URL https://www.dementiasplatform.uk/NTAD
 
Title Video of DPUK conference 
Description Video of highlights from the DPUK annual conference 2017. 
Type Of Art Film/Video/Animation 
Year Produced 2017 
Impact Use in the promotion of the 2018 annual conference amongst our key audiences. 
URL https://www.youtube.com/watch?v=TAsOtdaHkO0
 
Title Women and girls in sience campaign 
Description The campaign for Women and Girls in Science day 2020 (11 Feb) included a video of DPUK women researchers describing how working in science is exciting and challenging, a blog from a senior researcher on working in science and having a career break posted on the University of Oxford science blog pages and illustrations of DPUK researchers by illustrator Nina Chhita on Twitter and Instagram. 
Type Of Art Artefact (including digital) 
Year Produced 2020 
Impact The video and shorter video clips were viewed a total of 3,045 times Oxford Uni Tweeting of the blog received 20 retweets and 105 likes The DPUK social channels gained 38,325 impressions and 511 engagements DPUK Senior researcher's blog on the University of Oxford, Dept Psychiatry and DPUK website was viewed 2308 times 
URL http://www.ox.ac.uk/news/science-blog/seven-children-20-year-career-break-and-return-cutting-edge-de...
 
Description "Talented Women for a Successful Wales" report commissioned by the Welsh Government
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
URL http://gov.wales/docs/det/report/160308-women-in-science-en.pdf
 
Description ABN clinical research and academic committee, London representative
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description AI-MIND Consortium SAB
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
Impact The AI-MIND Consortium is to delivery new artificial intelligence methods to improve diagnosis and prognosis in dementia
URL https://accelopment.com/projects/ai-mind/
 
Description Academy Medical Sciences Council Member
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Academy Medical Sciences Fellow
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Academy Medical Sciences Wales Ambassador
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Advisor WHO (World Health Organisation)
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact N/A
 
Description Alzheimer Association Educational Workshop: The basics of fluid biomarkers in AD - speaker
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Alzheimer Research UK Scientific Advisory Board Chair
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact To ensure the £30m annual investment in dementia research is most effective, for long term health, social and economic benefit
 
Description Associate Director, UK Dementia Research Institute (UKDRI)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Attend technical meeting on the Implementation of the Global Action Plan on Public Health Response to Dementia
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Attendance to TRC-D Steering Committee Meeting
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://www.nihr.ac.uk/partners-and-industry/industry/collaborate-with-us/dementia.htm
 
Description Attended Association of British Neurologist's annual conference and delivered citation for ABN medallist
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description COVID advisory group
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Calman Training
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Canadian Consortium on Neurodegeneration in Aging (CCNA)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Chief Scientific Advisor to Alzheimer's Research UK
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Chief Scientific Advisor, Welsh Government
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Clinical Expert for a NICE Scientific Advice consultation on Alzheimer's Disease
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Contributor to a review of current dementia recruitment registers and its role for the public and research landscape
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description DPUK2Associate Director
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact DPUK is leading academic-industrial partnerships for dementia research, and coordinating the 'ecosystem' for dementia research and care in the UK. As associate Director and lead for Experimental Medicine, my role is to accelerate early phase clinical trials though partnerships with industry, academic and third-sector stakeholder collaborations
URL https://www.dementiasplatform.uk/
 
Description Dementia Programme Board - oversee the implementation of the PM's Challenge on Dementia to 2020
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Dementia Research Institute VIP Visit
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Deputy Chair, ABN Cognitive Disorders Advisory Group
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact N/A
 
Description Deputy Director DPUK
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
 
Description Dr M Malpetti - Invited contribution to the World Alzheimer Report 2021
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact Publication to serve as reference for students and practitioners.
URL https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf
 
Description EPAD LCS sample access committe
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Expert Advisor on Trond Mohn Foundation 2021
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
Impact The foundation continues to offer research grants to promising researchers from Norwegian universities and university hospitals.
 
Description Expert in government-supported monthly ADD Chip 5m cohort meetings
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact John Gallacher is a regular expert at monthly ADD Chip design meetings - a group which aims to form a cohort [supported by the UK Government, Charities and Industry (pharma, diagnostic & digital)] which looks to create the largest risk stratified population (including by genotype) in the world. It wants to involve 5 million healthy individuals, aged 40-75. Recent successes include ADD now being set up as a company limited by guarantee with one employee (Interim COO FR). CEO interviews have taken place and CEO could be in post as early as April. CRUK to host the CEO for the first year until the company has physical premises.
 
Description German Centre for Neurodegenerative Diseases (DZNE) scientific review
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description International Advisory Committee for Healthy Brains for Healthy Lives (HBBL), McGill
Geographic Reach North America 
Policy Influence Type Participation in a advisory committee
Impact The $100 million HBBL program seeks to improve the mental helath across Canada across all age groups.
 
Description Invitation to participate in Challenge on Dementia 2020 workshop - May 2019
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact John was personally invited to participate in a working group on research and funding as part of the government's review of the Challenge on Dementia 2020 on the afternoon of Friday 24th May. Earlier in 2019, the government published a report summarising the views of stakeholders on the progress of the Challenge on Dementia so far and set out actions for the remaining 2 years of the Challenge. The government is also looking beyond 2020 and invited stakeholders to identify priorities for a post-2025 strategy. As part of this work DHSC are facilitated 5 working groups to consider a maximum of 3 recommendations for each group. The 5 working groups will cover: 1. Technology 2. Research/funding 3. Dementia awareness 4. Risk reduction 5. Health and care delivery Martin Rossor and Hilary Evans were asked to chair the research/funding working group which will took place on Friday 24th May from 2pm-5pm in Conference Room 1, DHSC, 39 Victoria Street, London. John was asked to join these discussions and to help consider which 3 recommendations are priorities for the field to help us move the research forwards towards effective treatments.
URL https://www.gov.uk/government/publications/prime-ministers-challenge-on-dementia-2020
 
Description Invited abstract reviewing board member at Tau2022 conference - Dr M Malpetti
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
Impact Served as subject specific reviewer.
 
Description Invited abstract reviewing board member at the European Molecular Imaging Meeting - Dr M Malpetti
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
Impact Served as subject specific reviewer.
 
Description Invited as expert to contribute to discussion with Chris Whitty, Chief Scientific Adviser, Department of Health and Social Care re: polygenic testing to improve health
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact A draft final integrated table has been created, incorporating all inputs received, for Polygenic Risk Sscore performance for different diseases (integrated updated online version here: https://docs.google.com/spreadsheets/d/1XFbVkjpNeNexH6NvWzEcrQIF88ogQ9b6NPXy-FfeOCI/edit?usp=sharing). This table also includes the PRS generated by Genomics PLC across a number of disorders including their validations from UKBiobank. Albeit that we have amassed some very useful starter data on the spreadsheet, given the rich and diverse debate generated by this process, it seems the exam question we were set by Chris is far from answered. The next steps could be to: (i) agree a 'short-list' of conditions as being the currently most plausible (ii) examine in detail existing analyses for clinical impact and health economic impact for these disease use-cases (iii) evaluate predicted trajectory of PRS with future GWAS (ie what will PRS do in 5,10,15 years with delivery from additional GWAS) (iv) current research priorities for PRS evaluation/implementation. Breast Cancer, Coronary Artery Disease and ?colorectal cancer likely remain front-runners (driven primarily by population incidence). It was discussed whether further dialogue is warranted, and if so, what would be the best way of continuing it and bringing in those with the requisite focused expertise? For example, potentially another modest-sized closed meeting: delineated data-driven sessions focused on really unpicking health utility/specific diseases use cases and ways forwards.
URL https://www.gov.uk/government/people/christopher-whitty
 
Description Invited co-authorship for a systematic review - Dr M Malpetti
Geographic Reach Multiple continents/international 
Policy Influence Type Contribution to new or Improved professional practice
Impact Publication in a major journal.
 
Description Invited contribution to hot-topic series for the Journal of Nuclear Medicine - Dr M Malpetti
Geographic Reach Multiple continents/international 
Policy Influence Type Contribution to new or Improved professional practice
 
Description Invited leading figure to UK Dementia Ecosystem Summit (hosted by UK DRI)
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact John Gallacher was invited as a leading figure in dementia to invite to participate in a small meeting with other leaders of the UK Dementia Ecosystem to be held towards the end of March in central London. The meeting was an opportunity for him and other leaders to inform each other of their goals and aspirations, identify possible areas of synergy and collaboration and discuss the most pressing issues. Goals and achievements for the meeting included: Promote awareness of vision and goals of each participating organisation. - Define potential points of synergy and collaboration in the short, medium and long term, particularly in the following areas: • Development of tools for translational research and experimental medicine • Understanding the breadth of symptoms that make up the spectrum of dementia: communication between basic and clinical science • Care research and technology - Define a clear message engaging the Government to sustain dementia research.
URL https://ukdri.ac.uk/news-and-events/dementia-ecosystem-uk-action-through-alliance
 
Description Invited to review Clinical Trials Regulation by Medicines and Healthcare products Regulatory Agency (MHRA)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact This policy review has been launched following the United Kingdom's departure from the European Union. It aims to design a world-class sovereign regulatory environment for clinical trials that will support the development of innovative medicines and ensure that the UK retains and grows its reputation as world leading base for life sciences, generating opportunities for skilled jobs in the UK.
 
Description JGallacher contribution to IHCC Policy Working Group
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact John Gallacher contributed to the discussion surrounding streamlining policy development for the IHCC strategy. IHCC aims to create a global platform for translational research - informing the biological and genetic basis for disease and improving clinical care and population health. It includes the opinion of the PIs of the top 100 largest cohorts globally, so includes the work of DPUK.
URL https://ihccglobal.org/
 
Description JGallacher contribution to Our Future Health Design Group monthly meeting
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact JGallacher contribution to the design of one of the UK's largest cohort studies involving members of the public, including the application of online cognitive tests. Our Future Health will be the UK's largest ever health research programme, designed to help people live healthier lives for longer through the discovery and testing of more effective approaches to prevention, earlier detection and improved treatment of diseases.
URL https://www.closer.ac.uk/event/our-future-health/
 
Description JGallacher contribution to Register of Registers meeting - streamlining national efforts to recruit to dementia studies
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact JGallacher contribution to Register of Registers meeting - streamlining national efforts to recruit to dementia studies in order to remove barriers to members of the public and those part of cohort studies to sign up to research efforts. The meeting was attended by several register keepers and PIs to agree eg that the CSR/Great Minds effort should be listed on the Join Dementia Research webpage for improved visibility.
URL https://www.greatmindsfordementia.uk/dementias-platform-uk
 
Description JPND SAB Meeting - re-launching its Strategic Research and Innovation Agenda (SRIA)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Keynote presentation on DPUK at Westminster Health Forum policy conference - 'Improving dementia outcomes in England: research, personalised care and health and social care integration'
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact The agenda: Progress on meeting the goals of the Dementia 2020 Challenge and priorities for moving forward post-2020; Developing an integrated approach to improving dementia outcomes in Birmingham; Integrating health and social care - workforce development, creating dementia-friendly communities and the role of technology; Personalised care in practice - addressing barriers, increasing access and supporting patient choice; Key issues for regulating dementia services; Next steps for dementia research - funding, translating research into practice and improving patient participation: Supporting research to improve dementia outcomes; Data in the digital age for dementia research: Dementias Platform UK; Collaboration with industry partners: and Encouraging the translation of research into clinical practice.
URL https://www.westminsterforumprojects.co.uk/publication/dementia-care-in-England-19
 
Description Long-term and regular involvement in the IHCC Policy Working Group
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact John is a representative on the Policy team (Team C) for the formation of the International Hundred K+ Cohorts Consortium (IHCC). The IHCC represents the 100 largest cohorts globally (mostly those who include over 100k participants) and aims to improve the work of cohorts on an international scale,. IHCC have facilitated discussions on improving prospects for compatibility of cohort elements (e.g., instruments, data formats, phenotype measures, & consents), promoting data and specimen sharing & open access policies, examining potential for collaborative genome sequencing/analysis, and exploring feasibility of a searchable global cohort registry. The overall charge of the Policy Team is to create a policy agenda to facilitate and optimise impact of assembling cohorts. A draft IHCC Guidance for Collaboration with Industry has been created, with thoughts of also producing a publication.
URL https://ihcc.g2mc.org/teamc/
 
Description MRC Dementias Platform UK 'Open Science Champion' and Steering Group member
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
URL http://www.mrc.ac.uk/research/facilities-and-resources-for-researchers/dementias-platform-uk/governa...
 
Description Medicines Discovery Institute MDI
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Member of the Committee on the Medical Effects of Air Pollutants (COMEAP) advisory committee
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Member, Biobank access committee, Brains for Dementia Research
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description NIHT Translational Research Collaboration for dementia
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact To facilitate multilateral research across academic, healthcare and industrial partners in the UK, for better and faster dementia research. Reports to NIHR Office for Clinical Research Infrastructure (NOCRI)
URL https://www.nihr.ac.uk/partners-and-industry/industry/collaborate-with-us/dementia.htm
 
Description NMHRI management
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description National Core Studies
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact £7million funds for projects related to COVID: prediction, protection and prevention
 
Description Participation as expert in Population Research Resource landscape review - November 2019
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact John was invited as expert to comment on a landscape review and lessons learnt document from existing population research resource initiatives. Wellcome is working with the MRC and the ESRC to identify what kind of new Population Research Resource is required to capitalise on the rich longitudinal data and biological samples from the wealth of UK large-scale, long-term population based studies (including cohort studies). Their focus is on enabling cross-study research through the discoverability and sharing of longitudinal data and samples, linking these data with administrative, health and other routine records, and encouraging best practice. At the Population Research Resource Workshop held on the 24th May 2019 (which John also participated) a list of existing initiatives that support longitudinal population studies in the UK were identified, along with a list of functions that these initiatives may provide. Wellcome have now commissioned to write a short report by November 29th 2019 to provide them with a description and "lessons learnt" review of these existing initiatives. The first stage of the review was to provide a one-page summary of existing initiatives from publically available information on the websites of these initiatives that describes the resource, its purpose and objectives, and the functions provided. The second stage of the review was to contact the lead of each initiative by email to obtain further information to clarify these summaries that will form an appendix in the report. John completed an in-depth questionnaire and 1:1 interview on his view of the landscape.
 
Description Participation in an advisory committee - Alzheimer Research UK Scientific Advisory Board Chair (2021)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact ARUK is a major funder of Alzhiemer's disease related research in the UK. Serving as chair on this advisory board has had a significant impact in helping ARUK direct their funding towards areas of greatest impact, as well as helping researchers build effective collborations resulting in meaningful insights improving patient care and informing policy.
 
Description Press conference
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Proposal sent to UK Biobank titled 'Proposal: Subjective memory questions in UK Biobank'
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Proposal to UK Biobank titled 'Proposed cognitive tests for an enhanced UK Biobank cognitive battery'
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Reinvigorating health registries during COVID for rapid policy analyses
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
URL https://www.registerkonferansen.no/
 
Description Report sent to UK Biobank titled 'Observation of the enhanced UK Biobank cognitive assessment'
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Report sent to UK Biobank titled 'Recommendations on the retention of cognitive tests in the UK Biobank cognitive test battery'
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Report to UK Biobank on the UK Biobank cognitive assessment titled 'Test characteristics of the enhanced UK Biobank Cognitive Assessment'
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Representative on SAIL Databank Scientific External Advisory Board (Dec 2019)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact The SAIL Scientific External Advisory (SEA) Board discussed and generated actions in relation to topics such as new data types / usages and resulting information governance challenges; Data proportionality v. the demand for programme level data, and Development of a Public Involvement & Engagement policy/strategy for SAIL.
URL https://saildatabank.com/
 
Description Speaking at ARUK Policy conference: Looking forward: Towards dementia treatment - planning for the requirements to deliver new treatments for AD in the UK
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Standard Operating Procedures sent to UK Biobank - SOPs for IQCODE
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Strategic Coordination of Health of the Public Research Committee (SCHOPR) to develop a set of public health research principles and goals to guide funding decisions
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a national consultation
 
Description Talk at International Cohorts Summit, Iceland - April 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact IHCC convened the second International Cohorts Summit in Reykjavik, Iceland April 2019 with the intent of developing the scientific agenda to drive the research and collaboration between cohorts and present Team activities and progress on goals that were established as the result of the first International Cohorts Summit held in March 2018. The primary objectives of this meeting were to: Identify scientifically meritorious cross-cohort research projects and identify international collaborators willing to organize and participate in them Develop an IHCC scientific agenda to bring forward to funding bodies The International Cohorts Summit was conceived by the Heads of International Research Organizations (HIROs) chaired by Jeremy Farrar of the Wellcome Trust, with an inaugural summit held in March 2018 in Durham, North Carolina, USA, organized by the Global Genomic Medicine Collaborative (G2MC), with the goal of enabling leaders of large-scale longitudinal cohorts worldwide to share best practices, discuss data sharing, explore standards, discuss common challenges, and explore the potential for a large(r) collaborative sequencing strategy. From that Summit, the International HundredK+ Cohorts Consortium (IHCC) was formed, with teams assembled to address the actions identified in this Summit. John Gallacher was invited to contribute alongside the PIs of the most influential cohorts and their funders internationally to discuss remedies to challenges and opportunities faced by cohorts. This particular summit involved giving a pitch by Dr Sarah Bauermeister on behalf of Team C's work on policy. The pitch was on a precision medicine approach to multi-morbidity in cardio-metabolic disease and dementia, and the resources required for this. The DPUK Data Portal was demonstrated as a world-leading tool in data curation and analysis instrumental to the cause. Sarah was approached several times from international funding and policy leaders in the field, and engaged for further collaboration. One major impact was an invitation from China to attend a workshop discussing how DPUK and the Data Portal could aid research in Asia.
URL https://ihcc.g2mc.org/ics2019/
 
Description The Secure Anonymised Information Linkage System
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Trond Mohn Foundation
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
Impact Advisory committee for a major biomedical research foundation
 
Description UCL ageing event - cultivating research connections across the university: organising committee and plenary speaker
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description UK Biobank - long-term and regular attendance as a representative on the UKB Steering Committee
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact John is a long-term and regular representative at the tri-annual UKB steering committee meetings in London, as well as UKB's annual International Scientific Advisory Board. John provides expertise and leadership on cognitive and psychological assessments. His work for UK Biobank provides a regular touch-point for DPUK, with the platform benefiting from John's detailed and up-to-date knowledge UKB's resources and direction.
URL https://www.ukbiobank.ac.uk/steering-committee/
 
Description UK representative - European Academy of Neurology Dementia Panel
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description UK/Italy Imaging working group research partnership
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Vice Chair and Chair Elect, Advisory Council US Alzheimer's Association ISTAART
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description WHO's Global Dementia Observatory discuss the implementation of the global action plan on public health response to dementia 2017-2025
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description Work group to establish a Danish brain research centre - Lundbeckfonden, The Brain Prize
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Working Group Lead on Emeritus Professor John Bell's response to potential increase in Dementia governmental funding
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Following a recent a Conversative goverment pledge (https://www.bbc.co.uk/news/election-2019-50523507), it is anticipated that there will be significant new UK Government funding for dementia research. As additional funding will probably be focussed in areas identified as particularly challenging to drug discovery, it will probably leverage in considerable matched, pre-competitive industry funding. Further, it is likely that this investment will be in translational research - complementing existing Dementia Research Institute activity in basic research. In the -omics era major discoveries driven by genomics, proteomics and metabolomics have uncovered the key protein pathways, cellular pathology within the brain and the systemic effects of the disease involving the vascular system and the gut-liver-brain axis. In next decade, bridging the gap between target discovery and clinical interventions is one of the major challenges. The interest of industry appears to be focussed on target validation and human experimental medicine. To make a strong Oxford offer, it was proposed to need to take stock of current strengths and identify key gaps. It was thought this relevant work in Oxford takes place across multiple Departments and will require coordination, as will the relevant infrastructure. This aim of this workshop was to develop Oxford's strategy for expanding dementia research, maximising the potential for both local research and for collaborations with national programmes including the Dementia Research Institute (DRI), Dementia Platform UK (DPUK) and ARUK Drug Discovery Institutes (DDI). The three major areas of focus for the meeting included target discovery and validation; Big Data and multi-omics data integration, and Experimental Medicine. As a result of the meeting, John Gallacher was asked to be chair of one of the four working groups ('Biobanks/Clinical follow-up studies/Epidemiology'). A decision was taken to build Oxford's translational research offering in dementia to a higher level allowing Oxford to secure transformational funding in the £50m+ range from industry, government and philanthropic sources. Each group was asked to: i) map current landscape ii) map future landscape required iii) identify capability gaps. iv) Propose how we can fill capability gaps and outline a. the required capability i.e. new posts, new equipment, shared resources, new/existing technology, new approaches etc. b. the resources/funding required. c. a timeline e.g. if recruitment is required for a strategic appointment or new equipment is ordered/infrastructure built In a document structured as suggested above. John's working group was asked to identify a clinical lead seeing patients in Oxford to:- a. Ensure we are biobanking rich patient material in Oxford (CSF, skin biopsies etc..) b. Build up our UK clinical network in advance of the bid with inter-institutional alliances to complement our translational offering. A revised draft of a white paper is being produced, setting out the overall scientific vision. The more detailed granular output of the working groups will be fed into this i.e. the additional capability building required, resources necessary and implementation timeline.
 
Description World Dementia Council
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description "A multi-centre randomised controlled trial of the clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury"
Amount £1,988,751 (GBP)
Organisation NIHR London (South) CRN 
Sector Public
Country United Kingdom
Start 08/2021 
End 08/2024
 
Description "Clinician training partnership: vascular contribution to dementia": Clinical Training Partnership awarded to W Whiteley, JM Wardlaw, G Hardingham, CW Ritchie, C Smith, A Williams, K Horsburgh, H Whalley, S Munoz Maniega
Amount £225,000 (GBP)
Funding ID 3699 
Organisation Alzheimer's Society 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2019 
End 07/2022
 
Description "Dementias Platform UK" Co-applicant with principal applicant John Gallacher (Oxford) and co-applicants Ronan Lyons, James Rowe, Carol Routledge, Declan Jones
Amount £7,500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2021 
End 12/2025
 
Description "Integrative imaging of brain structure and function in populations and individuals" (awarded to Mark Woolrich)
Amount £570,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 12/2024
 
Description "Small Vessel Disease - Spotlight on Symptoms (SVD-SOS) - Improving recognition of symptoms and signs of progressing cerebral small vessel disease-related brain damage to prevent cognitive decline, dementia and stroke" (Doubal F, Wardlaw, JM)
Amount £24,962,394 (GBP)
Funding ID SA PG 19\100068 
Organisation Stroke Association 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2019 
End 07/2022
 
Description "Synaptic Health In Neurodegeneration" PI Prof James B Rowe Co-applicants Kia Nobre and Mark Woolrich
Amount £400,000 (GBP)
Organisation MRC Dementias Platform UK 
Sector Academic/University
Country United Kingdom
Start 09/2021 
End 09/2024
 
Description "UK DRI IPSC platform to model Alzheimer's disease risk (IPMAR) "
Amount £1,866,149 (GBP)
Organisation UK Dementia Research Institute 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 07/2023
 
Description "Wellcome Centre for Integrative Neuroimaging" (awarded to Kia Nobre and Mark Woolrich)
Amount £2,801,188 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2024
 
Description 1946 ARUK
Amount £1,824,093 (GBP)
Funding ID ARUK-PG2014-1946 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2014 
End 06/2017
 
Description A longitudinal amyloid-PET/MRI study of the 1946 birth cohort. ARUK-PG2017-1946.
Amount £1,216,062 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2017 
End 06/2019
 
Description A standardized, multilingual, mini linguistic state examination (MLSE) for classifying and monitoring primary progressive aphasia.
Amount £358,924 (GBP)
Funding ID RG82683 
Organisation St George's University 
Sector Academic/University
Country Grenada
Start 01/2017 
End 12/2019
 
Description A*-STAR Scholarship (Supervisor to Quyen Do). Advanced 3D co-culture iPSC-derived models of Parkinson's
Amount $206,382 (SGD)
Organisation Agency for Science, Technology and Research (A*STAR) 
Sector Public
Country Singapore
Start 01/2018 
End 09/2022
 
Description ABBUK Brains for Dementia Research Programme (extension)
Amount £2,598,988 (GBP)
Organisation Alzheimer’s Brain Bank UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 03/2021
 
Description ABBUK Brains for Dementia Research Programme (extension)
Amount £404,390 (GBP)
Funding ID 504291 
Organisation Alzheimer’s Brain Bank UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2013 
End 03/2018
 
Description ARUK Illustration Award 2021 given to Bryan Ng
Amount £200 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2021 
End 08/2021
 
Description ARUK ODDI collaboration: Phenotypic drug discovery in Parkinson's
Amount £200,000 (GBP)
Organisation University of Oxford 
Department Alzheimer's Research UK Oxford Drug Discovery Institute
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2020
 
Description ARUK Oxford Pilot Investigating the effect of tau on axonal transport and tau release in MAPT-iPSC cortical neuron models
Amount £4,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description ARUK Oxford Pilot Optogenetic light source and controller for 96/384-well plates to allow uniform illumination of wells inside a cell-culture incubator.
Amount £4,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description ARUK Pilot Analysis of tau secretion in iPS differentiated neuronal cultures
Amount £4,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description ARUK Pilot Award 2020-21 given to Dr Charmaine Lang & Mr Peter Kilfeather
Amount £2,297 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 08/2021
 
Description ARUK Pilot Award 2020-21 given to Maria Claudia Caiazza
Amount £2,500 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 08/2021
 
Description ARUK Travel Award 2020-21 given to Kaitlyn Cramb to attend & present at AD/PD conference in Barcelona
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2022
 
Description ARUK Travel Award 2020-21 given to Martha Lavelle
Amount £100 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2021 
End 09/2021
 
Description ARUK Travel Award 2020-21 given to Quyen Do to attend Ion channels in Synaptic and Neural Circuit Physiology online conference
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2021 
End 06/2021
 
Description ARUK Travel Award given to Ajantha Abey to attend ARUK Early Careers Day and Research Conference 2022
Amount £126 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2022 
End 03/2022
 
Description ARUK Travel Award given to Bryan Ng to attend ARUK Early Careers Day and Research Conference 2022
Amount £205 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2022
 
Description ARUK Travel Award given to Maria Claudia Caiazza to attend AD/PD conference 2022
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2022
 
Description ARUK Travel Award given to Mootaz Salman to attend Brain 2022
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2022 
End 07/2022
 
Description ARUK Travel Award given to William McGuinness to attend AD/PD conference 2022
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2022
 
Description ARUK Travel grant
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2019 
End 08/2019
 
Description ARUK network pilot grant
Amount £5,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 03/2019
 
Description Airwave Health Monitoring Study (AHMS)
Amount £23,908 (GBP)
Funding ID WPEA_P72447 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 06/2020 
End 06/2023
 
Description Ajantha Abey, The Clarendon Fund & Department of Physiology, Anatomy, and Genetics Scholarship. Project title: Understanding Selective Neuronal Vulnerability in Alzheimer's and Parkinson's Disease and Potential Remedies Through Patient-Derived Stem-Cells
Amount £125,097 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 09/2020 
End 09/2023
 
Description Alzheimer's Disease Data Enablement Fund sponsored project: Traumatic brain injury, emotional adversity and the long-term effects on adult outcomes and dementia.
Amount £612,845 (GBP)
Organisation National Philanthropic Trust 
Sector Charity/Non Profit
Country United States
Start 03/2019 
End 12/2019
 
Description Autophagic flux 
Amount £317,137 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 08/2017 
End 08/2019
 
Description Awarded an Oxford ARUK Small Equipment Award to purchase an Oxford Nanopore MinION
Amount £3,670 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2019 
End 07/2019
 
Description BHF Research Excellence Award
Amount £3,000,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 04/2024
 
Description BRC award to UCL/H (Dementia Theme)
Amount £5,000,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 03/2017 
End 04/2022
 
Description Becky Carlyle - Subcellular proteomic signatures of Alzheimer's disease.
Amount $64,000 (USD)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 01/2022 
End 12/2024
 
Description Biomedical Research Centre Dementia Theme
Amount £118,000,000 (GBP)
Funding ID RG85367 
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 03/2017 
End 03/2022
 
Description Brain Network Analysis in Neurodegenerative Tauopathies
Amount £22,391 (GBP)
Funding ID RG89925 
Organisation The Evelyn Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 12/2019
 
Description Brain Research Trust
Amount £219,355 (GBP)
Organisation Brain Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 03/2019
 
Description Brain Research Trust
Amount £219,355 (GBP)
Organisation Brain Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 03/2019
 
Description Brains for Demention Research Programme
Amount £225,571 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2013 
End 03/2018
 
Description Bridging the gap: biophysical models of human frontotemporal lobar degeneration
Amount £2,025,694 (GBP)
Funding ID 220258/Z/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2026
 
Description British Heart Foundation - Cardiovascular mechanisms linked to cerebral amyloid b deposition and cognitive decline: a sub study of INSIGHT 46
Amount £273,844 (GBP)
Funding ID PG/17/90/33415 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 04/2022
 
Description British Heart Foundation - NIHR - Bloomsbury Centre for clinical phenotyping (BBCP): infrastructure Grant
Amount £776,285 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 12/2019
 
Description Centre for Ageing and Dementia Research (CADR)
Amount £386,341 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description Cerebrovascular health in older adults at a genetic risk for dementia
Amount £3,970 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 08/2018
 
Description Clinical research infrastructure
Amount £6,995,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2015 
End 09/2020
 
Description Clinical research infrastructure
Amount £1,500,000 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 03/2016 
End 03/2016
 
Description Collaborative award: Integrative imaging of brain structure and function in populations and individuals. Co-applicant with lead applicant Stephen Smith, Saad Jbabdi, Mark Jenkinson, Karla Miller (University of Oxford), Christian Beckmann (Radboud)
Amount £4,106,203 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 12/2025
 
Description Compartmentalised calcium handling in dopamine neurons: importance for selective vulnerability in Parkinson's.
Amount £3,700,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2022 
End 04/2027
 
Description DRI Costs
Amount £1,123,799 (GBP)
Organisation UK Dementia Research Institute 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 08/2022
 
Description Dayne Beccano-Kelly Lockey Fund- for travel to World Parkinson's congress
Amount £500 (GBP)
Organisation Lockey Committee 
Sector Academic/University
Country United Kingdom
Start 02/2019 
End 04/2019
 
Description Deconvoluting the dementia phenotype using functional genomics and computational approaches
Amount £537,913 (GBP)
Organisation Government of Wales 
Department Welsh European Funding Office
Sector Public
Country United Kingdom
Start 01/2018 
End 10/2022
 
Description Deep and Frequent Phenotyping; combinatorial biomarkers for dementia experimental medicine
Amount £6,301,078 (GBP)
Funding ID MR/N029941/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2016 
End 09/2020
 
Description Dementias Platform
Amount £6,618,190 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2014 
End 06/2019
 
Description Dept MRC Studentship (Principal Supervisor to Naroa Ibarra Aizpurua, Co-supervisor Dr Sally Cowley; Understanding the contribution of astrocytes to Parkinson's.
Amount £15,900 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2020 
End 09/2022
 
Description Developing new therapeutic drugs in pre-clinical models of Parkinson's.
Amount $200,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 06/2021 
End 02/2023
 
Description Dr Andrea Loreto Sir Henry Wellcome postdoctoral fellowship. Project title: The role of the Wallerian axon-death pathway in neuronal and axonal vulnerability in Parkinson's disease
Amount £250,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 04/2022
 
Description Dr Charmaine Lang & Mr Peter Kilfeather were awarded an ARUK Thames Valley Pilot Award
Amount £2,297 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 06/2021
 
Description Dr Mootaz Salman was awarded an ARUK Thames Valley Network Small Equipment Award 2020
Amount £2,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2020 
End 03/2021
 
Description Dr Phillipa Carling was awarded an ARUK Thames Valley Network ECR award
Amount £349 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2020 
End 12/2020
 
Description Dr Sally Cowley Co-Investigator. Establishing a platform in human iPS-macrophages for interrogation of the STING pathway in Parkinson's.
Amount £123,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description Dr Sally Cowley Co-applicant/Co-supervisor. Targeting crosstalk between microglia, astrocytes and neurons in Alzheimer's disease pathology
Amount £500,000 (GBP)
Organisation Eli Lilly & Company Ltd 
Sector Private
Country United Kingdom
Start  
 
Description Dr Stefania Giussani was awarded an ARUK Thames valley network ECR Award
Amount £493 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2020 
End 12/2020
 
Description Drake Foundation: Effects of head injury the NSHD 1946 birth cohort.
Amount £60,852 (GBP)
Organisation The Drake Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 04/2019
 
Description Drake Foundation: Head Injury, cognition and imaging correlates of dementia in the Insight 46 cohort
Amount £60,852 (GBP)
Organisation The Drake Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 04/2019
 
Description EC ERASMUS+, European University of Brain and Technology (NeurotechEU) (awarded to Kia Nobre)
Amount € 422,000 (EUR)
Organisation European Council 
Sector Public
Country Belgium
Start 09/2020 
End 09/2023
 
Description EC Horizon, European University of Brain and Technology - Research & Innovation (awarded to Kia Nobre)
Amount £230,000 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 03/2021 
End 09/2023
 
Description ECR grant award for Bryan Ng
Amount £425 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2020 
End 03/2021
 
Description EM7 Connectivity changes in early Alzheimer's Disease.
Amount £94,384 (GBP)
Funding ID MC_ST_CBU_2019 
Organisation MRC Doctoral Training Program 
Sector Academic/University
Country United Kingdom
Start 09/2019 
End 09/2023
 
Description EM7 NTAD: new-therapeutics-in-alzheimers-disease
Amount £1,200,000 (GBP)
Organisation MRC Dementias Platform UK 
Sector Academic/University
Country United Kingdom
Start 05/2018 
End 09/2020
 
Description EM7 UCB-J PET
Amount £370,000 (GBP)
Organisation Janssen Research & Development 
Sector Private
Country Global
Start 08/2019 
End 06/2020
 
Description EU IMI-2. Amyloid imaging to prevent Alzheimer's disease (AMYPAD)
Amount £934,500 (GBP)
Organisation European Social Survey: European Research Infrastructure Consortium (ESS ERIC) 
Sector Charity/Non Profit
Country European Union (EU)
Start 09/2016 
End 09/2021
 
Description Early-onset depression: Characterising development and identifying risks
Amount £763,680 (GBP)
Funding ID MR/R004609/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2017 
End 11/2020
 
Description Elliot Mock - Validation of USP14 as a therapeutic target in Parkinson's disease.
Amount £150,000 (GBP)
Organisation Netherlands Organisation for Scientific Research (NWO) 
Sector Public
Country Netherlands
Start 09/2021 
End 09/2023
 
Description Enhancing autophagic flux in Parkinson's disease
Amount $663,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 09/2017 
End 09/2019
 
Description Expanding DPUK genetics and integrating with inflammation/immunity research
Amount £100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2019
 
Description FENS travel award for Bryan Ng
Amount € 75 (EUR)
Organisation Federation of European Neuroscience Societies (FENS) 
Sector Private
Country Belgium
Start 06/2020 
End 07/2020
 
Description Farr NLP open source software development
Amount £48,470 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2017 
End 10/2018
 
Description Functional screening of Parkinson's GWAS loci in human iPSC neurons
Amount £1,400,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 12/2020 
End 06/2024
 
Description GENetic Frontotemporal dementia Imaging - Second phase (GENFI-2)
Amount £2,613,582 (GBP)
Funding ID MR/M023664/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2015 
End 04/2020
 
Description Gates Ventures Interoperability Funding
Amount £612,845 (GBP)
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 02/2019 
End 04/2020
 
Description Genetics collaboration with Prof Bart De Strooper UK DRI programme
Amount £50,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2021 
End 04/2022
 
Description Genetics collaboration with Prof Bart De Strooper UK DRI programme
Amount £50,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2021 
End 04/2022
 
Description HDR UK Multiomics
Amount £77,625 (GBP)
Funding ID CFC0107 
Organisation Health Data Research UK 
Sector Private
Country United Kingdom
Start 03/2020 
End 03/2022
 
Description HDRUK
Amount £3,003,650 (GBP)
Funding ID NIWA1 
Organisation Health Data Research UK 
Sector Private
Country United Kingdom
Start 04/2018 
End 04/2023
 
Description HTA grant: : A multi-centre randomised controlled trial of the clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury (awarded to Vanessa Raymont)
Amount £1,988,751 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 08/2021 
End 08/2024
 
Description Harnessing the power of advanced imaging for dementia diagnosis
Amount $137,461 (USD)
Funding ID AARF-21-846366 
Organisation Alzheimer's Association 
Sector Charity/Non Profit
Country United States
Start 01/2022 
End 12/2023
 
Description High content imaging of iPSC-derived neurons to dissect mechanisms of Parkinson's
Amount £80,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 09/2021
 
Description Identifying genetic biomarkers of survival for bowel cancer to aid patient management
Amount £90,000 (GBP)
Organisation Tenovus Cancer Care 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 09/2022
 
Description Improving prevention trials in AD through imaging
Amount £249,965 (GBP)
Funding ID 261 (AS-PG-15-025) 
Organisation Alzheimer's Society 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 02/2017
 
Description Inflammation in frontotemporal lobar degeneration - from diagnosis and prognosis to clinical trials - Dr M Malpetti
Amount £495,687 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2022 
End 02/2027
 
Description Interrogation of the STING pathway in iPS cell models of Parkinson's. SA Cowley
Amount $289,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2022 
End 12/2024
 
Description JPND
Amount £350,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2016 
End 05/2019
 
Description JPND EUFIND
Amount £30,000 (GBP)
Organisation EU Joint Programme - Neurodegenerative Disease Research (JPND) 
Sector Public
Country European Union (EU)
Start 09/2016 
End 10/2017
 
Description Leveraging human genetics to identify target populations for dementia therapeutics (Eisai/DRI), project grant
Amount £200,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2020 
End 02/2023
 
Description MIND-MAPS
Amount £977,920 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2017 
End 03/2020
 
Description MJ Fox Therapeutic Pipeline Program: Enhancing autophagy flux in Parkinson's disease
Amount $330,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description MR/T033371/1 - DPUK2 Integrated Dementia Experimental Medicine
Amount £7,670,000 (GBP)
Funding ID MR/T033371/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2021 
End 12/2025
 
Description MRC CASE Award with Biogen (Principal Supervisor to William McGuiness. Molecular mechanisms of TFEB in Parkinson's
Amount £200,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2019 
End 09/2022
 
Description MRC COEN
Amount £150,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2016 
End 06/2018
 
Description MRC Momentum Award (Microglial interactions in Alzheimer's Disease)
Amount £4,300,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2017 
 
Description MRC Momentum Award (Microglial interactions in Alzheimer's Disease-informatics)
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description MRC Partnership Award (Dementias Platform UK Stem Cell Partnership)
Amount £1,200,000 (GBP)
Funding ID MR/N013255/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 06/2016 
End 06/2020
 
Description MRC Partnership grant for UK7T
Amount £220,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2016 
End 03/2019
 
Description MRC Project Grant MR/V013599: Identifying the regulation of striatal dopamine function by striatal astrocytes in health and parkinsonism (Prof S Cragg & Prof R Wade-Martins)
Amount £1,038,078 (GBP)
Funding ID MR/V013599 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 02/2021 
End 01/2024
 
Description MRC UK Dementia Research Institute Award - Dementia Bench to Bedside
Amount £6,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2017 
End 10/2022
 
Description MRC-KHIDI UK-KOREA PARTNERING AWARDS
Amount £100,000 (GBP)
Funding ID MC_PC_18006 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2017 
End 04/2018
 
Description MRC-NIH UK-US Dementia Research Collaboration programme
Amount £11,000 (GBP)
Funding ID MC_PC_17204 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2019
 
Description Mapping the Modulatory Landscape Governing Striatal Dopamine Signaling and Its Dysregulation in Parkinson's Disease.
Amount $9,000,000 (USD)
Organisation Aligning Sciences Across Parkinson's 
Sector Charity/Non Profit
Country United States
Start 11/2021 
End 10/2024
 
Description Maria Claudia Caiazza was awarded an ARUK Thames Valley network Pilot Award
Amount £2,500 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 06/2021
 
Description Mental Health Pathfinder Award
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Michael J Fox Foundation: In depth phenotypic profiling of PINK1/Parkin stem cell-derived neurons and glia.(Prof Wade-Martins)
Amount $600,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 08/2021 
End 02/2023
 
Description Michael J Fox Foundation: Transcriptomic changes in iPSC-derived dopaminergic neurons induced by exposure to alpha-synuclein revealed by single cell RNA-Seq.
Amount $200,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 03/2021 
End 09/2022
 
Description Michael J Fox Foundation: Validation of FASN as a target for therapeutic development in PD.(Prof Wade-Martins)
Amount $200,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 03/2021 
End 11/2022
 
Description Mootaz Salman - Organ-on-a-chip human patient stem cell models of the blood-barrier in Parkinson's disease.
Amount £115,000 (GBP)
Organisation The Leverhulme Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2022 
End 04/2025
 
Description NIHR Development and Skills Enhancement Award - Ivan
Amount £34,333 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 02/2021 
End 02/2022
 
Description Natalie Connor-Robson Lockey Fund- for travel to World Parkinson's congress
Amount £500 (GBP)
Organisation Lockey Committee 
Sector Academic/University
Country United Kingdom
Start 05/2019 
 
Description Natural Sciences and Engineering Research Council of Canada DPhil Scholarship, and Clarendon Award (Co-supervisors to Kaitlyn Cramb Prof. Richard Wade-Martins & Prof Stephanie Cragg ). In vitro iPSC-derived neuronal circuit models of Parkinson's
Amount £117,000 (GBP)
Organisation Natural Sciences and Engineering Research Council of Canada (NSERC) 
Sector Public
Country Canada
Start 09/2019 
End 09/2022
 
Description New Therapeutics in Alzheimer s Disease (NTAD) - ARUK
Amount £100,000 (GBP)
Funding ID RG89702 
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 08/2020
 
Description Oxford Biomedical Research Centre (BRC)
Amount £45,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start  
 
Description Oxford Medical Sciences Divisions Returning Carer Fund (Tara Caffrey)
Amount £5,000 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 02/2017 
End 05/2017
 
Description Peter Kilfeather awarded funding to study using spatial transcriptomics to look at SNpc and VTA gene expression on wild-type mice compared to SNCA-OVX mice.
Amount £22,151 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2021 
End 12/2021
 
Description Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability
Amount £48,502 (GBP)
Organisation Baily Thomas Charitable Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2019 
End 10/2020
 
Description Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability
Amount £48,502 (GBP)
Organisation Baily Thomas Charitable Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2019 
End 10/2020
 
Description Polygenic risk scores for neurodegeneration and Alzheimer's pathophysiology
Amount £951 (GBP)
Organisation UK Dementia Research Institute 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2020 
End 11/2021
 
Description Post-COVID cognitive impairment: characterisation and intervention
Amount £380,000 (GBP)
Organisation MQ Mental Health Research 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 11/2022
 
Description Post-Doctoral Fellowship (Supervisor to Dr Charmaine Lang): (£210,000; 01/10/19-30/09/21) New molecular targets in Parkinson's disease.
Amount £210,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 09/2019 
End 09/2021
 
Description Predicting dementia outcomes using simple, non-invasive assessments: a prospective population-based study
Amount £207,016 (GBP)
Funding ID MR/P001823/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2016 
End 07/2019
 
Description Profiling post-translational modifications of histone proteins as a determinant of Parkinson's susceptibility
Amount £232,404 (GBP)
Funding ID G-1502 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 07/2018
 
Description Rachel Heon-Roberts, Clarendon Fund & Dept of Physiology, Anatomy, & Genetics. Project title: Establishing a model of a-synuclein and amyloid-ß-induced mitochondrial & lysosomal dysfunction in Alzheimer's disease, PD & Lewy Body dementias
Amount £105,000 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 09/2021 
End 09/2024
 
Description Restoring noradrenergic function to improve apathy in Parkinson s disease to Claire O Callaghan
Amount £49,677 (GBP)
Funding ID RG90797 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2017 
End 07/2018
 
Description Rosetrees: Detecting and tracking brain changes in early Alzheimer's Disease
Amount £248,130 (GBP)
Funding ID M668-CD1 
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2017 
End 08/2020
 
Description SAIL Dementia eCohort
Amount £50,308 (GBP)
Organisation UK Dementia Research Institute 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 08/2021
 
Description SRUK winter studentship
Amount € 2,400 (EUR)
Organisation Society of Spanish Researchers in the United Kingdom 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Sanofi/Genzyme: Modulating GBA activity as a Parkinson's disease therapy
Amount £200,000 (GBP)
Organisation Sanofi 
Department Genzyme Therapeutics Ltd
Sector Private
Country United Kingdom
Start 11/2016 
End 10/2017
 
Description Senior Research Leaders Discretionary Award
Amount £15,000 (GBP)
Organisation Health and Care Research Wales 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2022
 
Description Stefania Guisanni was successful with an ARUK ECR video awards
Amount £320 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2021 
End 12/2021
 
Description Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders
Amount £310,234 (GBP)
Funding ID 209176 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2018 
End 06/2022
 
Description Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders
Amount £310,234 (GBP)
Funding ID Judith Allardyce 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 12/2021
 
Description TRanslating Individual Alzheimer GEnetic risk into disease phenotypes [TRIAGE]
Amount € 420,000 (EUR)
Organisation JPND Research 
Sector Academic/University
Country Global
Start 04/2020 
End 04/2023
 
Description Targeting HDAC4 in Parkinson's disease
Amount £50,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 02/2021
 
Description Targeting disease phenotypes in Parkinson's patient iPSC-derived dopamine neurons
Amount £650,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 09/2020 
End 09/2022
 
Description The Airwave Health Monitoring Study (AHMS). An Occupational Cohort Study of the British Police Forces
Amount £1,941,097 (GBP)
Funding ID MR/R023484/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2018 
End 04/2023
 
Description The UKDRI IPSC Platform to Model Alzheimer's Disease Risk (IPMAR). SA Cowley
Amount £1,770,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2021 
End 12/2023
 
Description The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects
Amount £288,555 (GBP)
Funding ID 104210 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description The physiology of dementia: magnetoencephalographic investigation of brain networks in frontotemporal lobar degeneration and Alzheimer's disease in preparation for experimental medicine studies.
Amount £49,592 (GBP)
Funding ID RG84879 
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 09/2017
 
Description Transcriptomic changes in iPSC-derived dopaminergic neurons induced by exposure to alpha-synuclein revealed by single cell RNA-Seq.
Amount $200,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 06/2021 
End 02/2023
 
Description Transcriptomic changes in iPSC-derived dopaminergic neurons induced by exposure to alpha-synuclein revealed by single cell RNA-Seq.
Amount $200,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 08/2021 
End 02/2023
 
Description Travel grant for conference for Bryan Ng
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2019 
End 03/2019
 
Description Travel grant for conference for Bryan Ng
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 03/2020
 
Description Travel grant for conference for Bryan Ng
Amount £300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 03/2020
 
Description UKRI Innovation / Rutherford Fund Fellowships at HDR UK
Amount £560,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 02/2018 
End 02/2021
 
Description Uniting iPSCS and CRISPR/Cas9 screens- a platform to model and interrogate genetic disease in Oxford
Amount £80,000 (GBP)
Organisation University of Edinburgh 
Department Institutional Strategic Support Fund
Sector Charity/Non Profit
Country United Kingdom
Start 12/2017 
End 06/2019
 
Description Validating prognostic biomarkers for colorectal cancer and determining their clinical utility
Amount £155,801 (GBP)
Organisation Cancer Research Wales 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2018 
End 10/2021
 
Description WP7 ARUK Pilot Award: "Disentangling contributions of the hippocampus and striatum in efficient memory-guided attention"
Amount £3,990 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2020 
End 08/2020
 
Description WP7 EU Innovative Training Network: European School of Network Neuroscience (awarded to Kia Nobre & Mark Woolrich)
Amount € 3,966,875 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 09/2019 
End 10/2023
 
Description WP7 German Research Foundation Fellowship to Dr Anna-Katharina Bauer (supervisor Kia Nobre)
Amount € 60,000 (EUR)
Organisation German Research Foundation 
Sector Charity/Non Profit
Country Germany
Start 08/2019 
End 08/2021
 
Description WP7 Marie Sklodowska-Curie Postdoctoral Fellowship to Dr Méadhbh Brosnan (supervisor Kia Nobre)
Amount € 212,934 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 08/2019 
End 08/2021
 
Description WP7 Oxford-Berlin Collaboration: "Dynamics of memory systems in the brain" (awarded to Kia Nobre)
Amount € 25,000 (EUR)
Organisation University of Oxford 
Department Oxford–Berlin Research Partnership
Sector Academic/University
Country United Kingdom
Start 01/2020 
End 12/2020
 
Description WP7 Royal Society Newton Advanced Fellowships and Mobility Grants to Dr André Cravo
Amount £60,000 (GBP)
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2019 
End 08/2021
 
Description Wales/NI substantive site. HDR UK
Amount £3,003,650 (GBP)
Organisation Health Data Research UK 
Sector Private
Country United Kingdom
Start 04/2018 
End 04/2023
 
Description Wellcome Centre for Integrative Neuroimaging - extension
Amount £3,101,188 (GBP)
Funding ID 203139/A/16/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 04/2024
 
Description Wellcome Integrative Neuroimaging Seed funding - £12,000 . Natalie Connor-Robson
Amount £12,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Wellcome Trust Clinical Research Training Fellowship
Amount £174,791 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Bloomsbury Centre
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 03/2019
 
Description Wellcome Trust Clinical Training Fellowship
Amount £174,791 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Bloomsbury Centre
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 03/2019
 
Description Wellcome Trust DPhil Studentship in Neuroscience: Characterisation of a novel GBA-L444P BAC transgenic mouse model of Parkinson's. (Supervisor to Tara Diviney, Co-Supervisor Prof Stephanie Cragg
Amount £104,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2020 
End 09/2023
 
Description Weston Brain Institute - Developing blood based biomarkers to detect pre-clinical Alzheimer's disease and predict progression
Amount £329,663 (GBP)
Organisation Weston Brain Institute 
Sector Private
Country Canada
Start 12/2020 
End 12/2020
 
Description Weston Brain Institute - Developing blood based biomarkers to detect preclinical Alzheimer's disease and predict progression
Amount £329,663 (GBP)
Organisation Weston Brain Institute 
Sector Private
Country Canada
Start 01/2018 
End 10/2020
 
Description What makes strategic stroke strategic? Multimodal imaging and network methods to predict dementia after strategic stroke
Amount £4,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 08/2017
 
Description Wolfson Foundation: Ageing Cohort
Amount £887,193 (GBP)
Organisation The Wolfson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2013 
End 03/2019
 
Title Alzheimer's Disease Data Intiative (ADDI) Workbench 
Description Development of a proof of concept system for international data platform data sharing and collaboration. The tool is available to other members of the international working group.. 
Type Of Material Improvements to research infrastructure 
Year Produced 2020 
Provided To Others? Yes  
Impact Development of technology solutions for data cataloguing, data identification and federated computation that can facilitate greater cross-platform data access and therefore scientific developments. 
 
Title BIOFIND output 
Description The JPND BioIND project was led from MRC-CBU, as an international collaboration to standardize and harmonize methods for dementia research. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2019 
Provided To Others? Yes  
Impact Data sharing across sites, the open science methods and a publication pending are outputs related to the validation and recommendations made. The research tool is part of the growing recognition of MEG's potential to transform dementia research, with novel mechanistic insights and trials outcomes, provided that industry-readiness benchmarks can be met. 
URL http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/closed-calls/brain-im...
 
Title CRISPR gene editing 
Description We have been able to establish CRISPR/Cas9 gene editing in our lab as a result of this project 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact We have been able to perform gene editing in iPSC lines. 
 
Title DPUK Data Portal 
Description The DPUK Data Portal has been relaunched to include a seamless transition from the DPUK main welcome site into the research infrastructure. The Portal, hosted by Swansea University, now includes openly available metadata on the DPUK cohorts, as well as information on the various parts of the infrastructure, which include: Portal analysis environment powered by virtual desktop infrastructure, imaging platform powered by XNAT, genetic platform created by Digital Health Labs, data linkage possibilities using world-leading matching technology, and a new and easy-to-use application form for researchers to apply for access to data, based on categorised dementia-specific data ontologies. The Portal is now supporting data access applications with dedicated resource to manage this process, and data management based on consultation with other data consortia and the cohorts themselves is underway using novel data management infrastructure (research data appliance based at Swansea University), enabling governance to remain entirely with the data provider and data access permissions to be managed by a central facility. 
Type Of Material Improvements to research infrastructure 
Year Produced 2017 
Provided To Others? Yes  
Impact The relaunch of the Portal has seen a surge in scientific collaboration in DPUK - for the period November 2017-January 2018, there are 12 live studies on the Portal, all using multiple cohorts and all cross-institution, including internationally-led studies from Maastricht University and the University of Hong Kong. These studies have primarily phenotypic data as their main modality, however we are also seeing the combination of phenotypic, genotypic and imaging data in studies, thus showing the power of a central system for accessing and analysing data from previously disparate sources. Genetics and imaging work packages are also contributing to the studies being supported by DPUK, and the Portal is making data available to specialists in these areas in order for them to derive services for the epidemiological community to make use of data that was previously unobtainable, either due to access difficulties or specialist intervention being necessary. 
URL https://portal.dementiasplatform.uk/
 
Title DPUK Data Portal Datathon Virtual Desktop 
Description Bespoke virtual desktop infrastructure for DPUK Datathons - comprising of dedicated 32GB RAM/4 CPU machines supporting up to 60 concurrent users. Pre-loaded with software such as Stata 16, SPSS, SAS, R, Python (Anaconda), PyCharm, Spyder, Jupyter Notebook, Eclipse, SQL Server Management Studio, Matlab, and Office. 
Type Of Material Improvements to research infrastructure 
Year Produced 2018 
Provided To Others? Yes  
Impact The dedicated Datathon desktop has allowed us to run 4 DPUK Datathon events across the UK, which have had an international audience of over 150 researchers cumulatively. 
URL https://portal.dementiasplatform.uk/
 
Title DPUK Imaging Network- Harmonising of Imaging protocols 
Description One important aspect of the work of the DPUK Imaging Network is the harmonising and optimising of protocols for image data acquisition, reconstruction, and analysis. This is currently in progress. There is a dedicated website for the MR/PET Partnership, a sub-group within the Imaging Network. The harmonised protocols will appear here once available: https://www.dpuk-mripet.info/ 
Type Of Material Improvements to research infrastructure 
Year Produced 2018 
Provided To Others? Yes  
Impact Complete harmonisation has yet to be achieved but this should happen in the first half of 2019. 
 
Title DPUK Stem Cell Network iPSC directory resource for researchers 
Description Members of the DPUK Stem Cell Network have produced a directory listing over 100 iPSC lines that could be made available to researchers in collaboration with the labs who generated the lines. The directory can be found on the DPUK website. It is available via the DPUK website and contact being made with the lead researcher who generated the lines. 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? Yes  
Impact The Stem Cell Network has published a range of papers using the resource. For an illustrative example please see a recent 2019 paper from the laboratory of Professor Richard Wade- Martins, the lead of the Stem Cell Network. https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg/ddz038/5315478 
URL https://www.dementiasplatform.uk/for-researchers/expert-communities-1/stem-cells-network-1/ipsc-reso...
 
Title Dementia Diagnosis Algorithm for use in primary care, hospital admissions or mortality datasets 
Description The researchers from DPUK WP9 used data from ~17,000 UK Biobank participants to identify participants with one or more dementia codes in primary care, hospital admissions or mortality datasets, and compared the coded data to the full-text medical record. Having validated the accuracy of these datasets, they then developed algorithms that can be applied to identify participants with dementia in UK Biobank and other DPUK cohorts. The authors will continue this promising work by investigating sources of potential bias in the data and the generalisability of these findings to older ages and other geographical areas. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2019 
Provided To Others? Yes  
Impact This is an initial validation study which has proved that the methodology works. Following recent publication of the results (March 2019) the work will be expanded and the findings built-on. 
 
Title Dementias Platform UK: Cognitive Test Directory. 
Description Dementias Platform UK: Cognitive Test Directory. Oxford, UK: DPUK; 2019. for use on the DPUK Data Portal 
Type Of Material Improvements to research infrastructure 
Year Produced 2019 
Provided To Others? Yes  
Impact Calvin C, et al. Dementias Platform UK: Cognitive Test Directory. Oxford, UK: DPUK; 2019. Downloadable from: https://www.dementiasplatform.uk/for researchers/get-ahead-with-cognitive-test-data-1/cognitive-test-directory 
URL https://www.dementiasplatform.uk/for%20researchers/get-ahead-with-cognitive-test-data-1/cognitive-te...
 
Title Development of an enhanced Cognitive Assessment for UK Biobank 
Description A DPUK funded group (WP10) led by Ian Deary in Edinburgh are working closely with UK Biobank to develop an enhanced cognitive assessment, including tests of cognitive function known to be sensitive to ageing. This includes more detailed tests of declarative memory, reasoning and executive function. There are some limitations of the scope for the tests; a brief period of time is allowed for testing to fit with any planned clinical visits for UK Biobank participants and it has to be self-administered on a computer touch screen. The group has produced a report for UK Biobank on the enhanced UK Biobank cognitive assessment and provided their preliminary assessment of the test characteristics. Subject to UK Biobank approval, it is hoped to provide details of the tests on the DPUK website. Preliminary report to UK Biobank is dated 21.09.2017 and is in the process of being updated. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2017 
Provided To Others? Yes  
Impact There has been a revision of the tests administered in UK Biobank and an improvement in their quality. This means that they are now more informative for investigating the variety and subtlety of cognitive changes seem in both healthy and pathological ageing. 
 
Title Dopamine neuron microfluidics 
Description Development of stem cell-derived neuronal culture techniques using microfluidic devices to channel axonal growth. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Provided To Others? No  
Impact Not yet: it is ongoing development 
 
Title Generation of MAPT CRISPR gene edited iPSC lines 
Description We have generated 8 QCed MAPT-­/-­ knockout lines on 2 control backgrounds. 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact We will use the MAPT-/- iPSC-derived neurons to study the role of MAPT in Parkinson's 
 
Title Generation of SNCA CRISPR gene edited iPSC lines 
Description We have generated 3 QCed SNCA-­/-­ knockout lines on control background and isogenic correction of SNCA Triplication patient line (and also knockout) - clones identified by droplet digital PCR, undergoing confirmatory sequencing. 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact Generation of SNCA CRISPR gene edited lines will further our work on the role of macrophages and microglia on the uptake/processing/secretion of alpha-­synuclein and its role in stimulating the immune response and enable us to interrogate the mechanism for the phagocytosis defect phenotype observed in the SNCA-­Triplication macrophages/microglia. 
 
Title High content, high throughput analysis 
Description The ability to perform detailed high-throughput analysis of neurons in culture 
Type Of Material Technology assay or reagent 
Year Produced 2016 
Provided To Others? Yes  
Impact Shared use of best practice in high-throughput analysis using Opera Phenix imager and high-throughout plate readers 
 
Title In vitro electrophysiology 
Description Patch-clamp techniques to measure neuronal activity of stem cell-derived neurons 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Analaysis of stem cell-derived neurons: dopamine neurons, cortical neurons, motor neurons and medium spiny neurons 
 
Title Live cell imaging techniques in iPS-derived DA neurons in vitro 
Description We have optimised a live cell imaging protocol for the visualisation and measurement of mitochondrial membrane potential in differentiated neurons. 
Type Of Material Cell line 
Provided To Others? No  
Impact The membrane potential-sensing dye TMRM can be used to quantify membrane potential, with increased fluorescence indicating increased membrane potential. 
 
Title Microglia differentiation 
Description The ability to generate microglia from human stem cells from dementia patients 
Type Of Material Cell line 
Provided To Others? No  
Impact We will be able to compare the function of microglia generated from patients and from controls 
 
Title PLA in stem cell neurons 
Description To enable the detection of a-syn oligomers in stem cell-derived dopamine neurons 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The detection of a-syn oligomers in stem cell-derived dopamine neurons 
 
Title Pipelines for processing MR data 
Description Novel pipelines for processing MR data (in conjunction with DPUK imaging platform) 
Type Of Material Improvements to research infrastructure 
Year Produced 2016 
Provided To Others? Yes  
Impact Establish pipelines to process MR data and combine that data in an imaging platform used by other DPUK cohorts 
 
Title Pipelines for processing PET data from PET/MR 
Description Creation of novel pipelines for processing PET data from PET/MR 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact These pipelines allow for improved efficiency and accuracy in the processing of PET data that is received from a PET/MR scanner. 
 
Title RNA-Seq 
Description Development of methods for analysis of RNA-Seq 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Understanding of gene expression profiles in selected cell population 
 
Title Target discovery assays 
Description Develop target discovery assays using high throughput screens 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact New research facilty built for our work 
 
Title iPSC phenotypic screens 
Description We have developed an organelle calcium flux assay for high-throughput screening and applied the assay to screen 4000 small molecules in Parkinson's patient iPSC-dervied dopamine neurons. 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact We will use the assay to identify new therapeutic targets or novel and or repurposable small molecule therapeutics. 
 
Title Alzhemer's Disease Polygenic Risk Profiling 
Description This model used data from the powerful dataset comprising 17 008 cases and 37 154 controls obtained from the International Genomics of Alzheimer's Project (IGAP). Alzheimer's disease (AD) Polygenic risk scores were generated for 3177 cases and 7277 controls (GERAD data) and tested whether the alleles identified to associate with disease in IGAP sample are significantly enriched in the cases relative to the controls in the GERAD sample. The disease prediction accuracy was investigated in a sample of 3049 cases and 1554 controls (for whom APOE genotype data was available) by means of sensitivity, specificity, area under the receiver operating characteristic curve (AUC) and positive and negative predictive values. The best prediction accuracy AUC = 78.2% (95% confidence interval 77-80%) was achieved by a logistic regression model with APOE, the polygenic score, sex and age as predictors. 
Type Of Material Computer model/algorithm 
Year Produced 2016 
Provided To Others? Yes  
Impact This approach is used to create SNP arrays for AD prediction (for research only so far). 
 
Title C-Surv Ontology 
Description The C-Surv ontology was finalised for the curation of DPUK Cohort Data. The onotology is comprised of 20 top-level and 140 2nd-level categories and all cohort data are categoried according to these. Standardisation of naming structure is an ongoing programme across all cohorts. Also, harmonisation of a 30-variable minimal dementia-focused dataset and updating of the DPUK Data Portal metadata tools, according to the C-Surv ontology. 
Type Of Material Data handling & control 
Year Produced 2019 
Provided To Others? No  
Impact Paper has been written, awaiting submission. The model may be adopted by cohorts and other interested parties as the standard for cohort data curation. 
 
Title Cam-CAN 
Description Cam-CAN project extended to include subarm of "Cam-CAn Frail" and early dementia participants. 
Type Of Material Database/Collection of data 
Year Produced 2016 
Provided To Others? Yes  
Impact Extensive applications for data from CC700; Cam-CAN-Frail still in data acquisition phase. 
 
Title Cerebrovascular Diseases Image Databank 
Description Cerebrovascular Diseases Image Databank contains brain magnetic resonance & computed tomographic imaging data from patients with cerebrovascular diseases, created by Professor Joanna Wardlaw. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
Impact Publicly accessible data-bank, improving research results across study groups focused on developing prevention and treatment methods for small vessel diseases, stroke and Alzheimer's disease. 
URL https://www.ed.ac.uk/clinical-sciences/edinburgh-imaging/research/themes-and-topics/analysis-and-pro...
 
Title Clinical Studies Register 
Description The Clinical Studies Register is an opt-out database. DPUK manages this database of willing AIRWAVE cohort participants for re-contact in clinical trials. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact The Clinical Studies Register holds approximately 50,000 participant records. The success and learnings of the Clinical Studies Register lead to the development of Great Minds, an opt-in register for participants who are willing to undergo deeper and more frequent geno- and phenotyping to add to their cohort records. 
URL https://www.dementiasplatform.uk/our-impact/trails-readiness
 
Title DPUK 7T data sharing 
Description Agreement on data sharing for 7T images using DPUK XNAT platform 
Type Of Material Database/Collection of data 
Year Produced 2016 
Provided To Others? Yes  
Impact pending 
 
Title DPUK Genomics portal 
Description The DPUK Genetics portal provides a collaborative platform for individuals, DPUK cohorts and the wider research community to share and access research outputs from genetic research. The platform provides two key tools for finding, sharing and analysing genetic data; The Results Registry tool, accessible via the main DPUK web portal, allows searching and uploading of genetic results data. This tool provides a rich set of search tools specific to genetic data and includes visualisation using the popular JBrowse genomic browser. This tool will allow users to share this data. This can be done under secure data transfer agreements if necessary. The second tool is the Genetic Data Browser this is available exclusively within the secure DPUK infrastructure. This will allow users to create cross-cohort comparison studies based on genotypic datasets and linked phenotypic data. This tool provides an interactive dashboard which can pull in phenotypic data and genetic markers from GWAS data and allow users to intuitively explore, combine and export patient cohorts. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact The DPUK Genetics portal, housed on the DPUK platform, allows non bioinformatic-expert users to explore components of genetic data within a secure environment. We have provided access to an international consortium, GERAD, via the DPUK data portal. This is a dataset of over 18,000 cases and controls (detailed in Table 2), as well as over 5,600 samples to date submitted to the EADB, the European AD DNA bank for deciphering the missing heritability of Alzheimer's disease 
URL https://portal.dementiasplatform.uk/
 
Title DPUK Imaging Platform 
Description Brain scan data from the imaging centres across the UK are brought together in the DPUK imaging platform - a database for anonymised brain scans from the cohort studies. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact The DPUK Central XNAT instance allows users to upload, manage and then share their imaging data with the Imaging Hub. The Imaging Hub allows researchers to identify cohorts of images that they wish to access, coordinate the access procedure, and create projects containing approved data for review and analysis. 
 
Title DPUK Re-imaging MRI Database 
Description The database contains MRI scans of brain and body together with self-reported health data from computerised questionnaires. The information follows the latest standard protocol in the UK Biobank imaging sub-study. This database relates to Work Package 3 of the DPUK award, relating to the re-imaging project with UK Biobank. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? No  
Impact The collection of data is ongoing with a target of re-imaging 10,000 subjects from the 100,000 UK Biobank participants in their imaging subs-study. This data collection is was financially (partially) supported from the DPUK award and the protocol to establish the repeat imaging protocol were developed by the DPUK research team. The major impact will come when the full dataset is complete and available to DPUK collaborators for analysis and planning of dementia related trials. The main indirect impact is that UK Biobank are now seeking philanthropic funding to extend on this project and increase repeat imaging numbers to ~70,000. These impacts were made possible by the initial imaging fund awarded to Newcastle, which leveraged a further £8M award from the MRC to UKB for whole repeat body imaging. 
 
Title Early Adversity and Dementia Programme 
Description This is a DPUK research programme for investigating the impact of early adversity on longitudinal cognitive decline and dementia. Lead by Dr Sarah Bauemeister, a team of 4 analysts work on different statistical and machine-learning models, across multiple cohorts and multi-modal data to investigate this topic. 
Type Of Material Computer model/algorithm 
Year Produced 2018 
Provided To Others? No  
Impact One paper submitted to BioRxiv https://www.biorxiv.org/content/10.1101/749077v1 and four pending papers in progress. A DPUK Discovery award and an MRC UK-Korea award were awarded for this programme, and Gates Ventures are funding its continuation through the ADDI interoperability project (scientific use-case). 
 
Title Great Minds 
Description An opt-in database of over 2000 participants from UK-based cohorts who are willing to participate in clinical trials and enhance their phenotyping through eg CANTAB online cognitive tests and Mezurio game as a phone application. Some of these may also under genotyping for greater depth of detail. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? No  
Impact A potential phenotypically rich register of pre-symptomatic healthy people with existing cohort data who are ready to engage with experimental studies to help understanding of dementia. Over three-quarters have engaged with regular online cognitive testing. 
URL https://www.greatmindsfordementia.uk/
 
Title Great Minds CRM recontact platform connects studies with volunteers with specific characteristics 
Description The Great Minds CRM platform is the system by which pseudo-anonymised Great Minds registry data is connected to contact and preference information and allows research assistants to invite identified volunteers with approved studies. 
Type Of Material Data handling & control 
Year Produced 2020 
Provided To Others? No  
Impact The pilot stage has allowed research assistants to securely match a study with volunteers with specific characteristics and manage oversee the engagement - whether the participant agree to join, whether the study claimed the volunteer, whether the study is complete etc. 
 
Title Insight46 XNAT database 
Description A bespoke database has been designed for the collection of Insight46 data that is run on the XNAT platform. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact This bespoke database allows for the collection of all study data in one location. Study data can be easily shared with authorised users and raw data can be easily downloaded for analysis. 
 
Title SAIL Dementia eCohort (SAILDeC) 
Description DPUK has funded the creation of the SAIL (Secure Anonymised Information Linkage) Databank Dementia eCohort, known as SAILDeC. A team from the University of Edinburgh, led by Dr Tim Wilkinson and Dr Christian Schnier, have developed a research cohort from routine healthcare records found in the SAIL Databank, a research databank containing routine healthcare and adminstrative records for the Welsh populace. The eCohort is derived from 1.2 million individuals who met the inclusion criteria, and of those, ~130,000 dementia cases throughout the data coverage have been identified. This represents the first UK research-ready disease cohort derived solely from routine healthcare records, which can be analysed in its own right or combined with other rich sources of cohort and routine data. It is thought that the technical components of creating the cohort, in terms of coding and initial analysis, could be the lead for future eCohort generation in other disease fields. These eCohorts could then be analysed within their specific area of science, or combined for a rich multi-morbidity database. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact This is the first disease-specific eCohort of patients to be created from ~20 years of routine healthcare data. It provides a rich dementia-specific resource for episodic progression of patients with initial MCI through to mortality, and every stage in between. The process of creating the cohort can inform the creation of such cohorts from the SAIL source and other routine clinical data sources in many disease areas. 
 
Title iPSC resource for researchers 
Description iPSC resources available are listed on DPUK website where they can download iPSC directory provides the opportunity for researchers to formally request over 100 stem cell lines derived from healthy and diseased individuals 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact Valuable way for researchers to find out about available resource 
URL https://www.dementiasplatform.uk/for-researchers/expert-communities-1/stem-cells-network-1/ipsc-reso...
 
Description AMYPAD 
Organisation Amyloid Imaging to Prevent Alzheimer's Disease
Country European Union (EU) 
Sector Public 
PI Contribution JMS is UCL lead for AMYPAD at UCL - which has interdependencies with DPUK through EPAD
Collaborator Contribution Design of protocols
Impact Project recently commenced
Start Year 2016
 
Description ARUK's DEMON network and DPUK Reach partnership 
Organisation Alzheimer's Research UK
Department Alzheimers Research UK, Cambridge
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Dr Sarah Bauermeister sits on ARUK's Deep Dementia Phenotyping ('DEMON') steering group. DEMON is a national network for data science and AI in dementia research - connecting together to work on new analytical solutions for dementia research.
Collaborator Contribution DPUK Reach is a Data Portal and/or ECR online support user group. It supports DEMON's aims by hosting a forum website which allows researchers to discuss cohorts, analyses, codes, statistical approaches, events and more.
Impact DPUK Reach has been launched as a way of DPUK Datathon participants to prepare and carry on for their Data Portal analyses,
Start Year 2019
 
Description ASAP SynTau: Alignment and Standardization of Neuroimaging Methods in Atypical Parkinsonism, specifically Synucleinopathies and Tauopathie 
Organisation EU Joint Programme - Neurodegenerative Disease Research (JPND)
Country European Union (EU) 
Sector Public 
PI Contribution This Working Group brings together neuroimaging experts from all over the world to develop a broad, community-based consensus on imaging protocols. These outcomes will help pave the way for the integration of neuroimaging in large and longitudinal multi-centre studies in AP, including therapeutic trials. Meetings, harmonisation of imaging data, workshops, and later data sharing.
Collaborator Contribution Meetings, harmonisation of imaging data, workshops, and later data sharing.
Impact A project initiation report is submitted to JPND. Data sharing agreements are in progress.
Start Year 2016
 
Description Abeta functional assays 
Organisation University of Oxford
Department Department of Psychiatry
Country United Kingdom 
Sector Academic/University 
PI Contribution We have worked to develop improved in vitro analysis odf Abeta function
Collaborator Contribution Collaborative development of assay
Impact Ongoing collaboration
Start Year 2015
 
Description Alan Turing Institute Datathon - a collaboration between ATI, Deep and Frequent Phenotyping and DPUK 
Organisation Alan Turing Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Data scientists from many different backgrounds combined their expertise to take on dementia in an unusual format for disease research: a three-day datathon. The intensive research event saw teams come together to work on data that is now available in the DPUK Data Portal. The datathon was jointly organised by DPUK, the Deep and Frequent Phenotyping (DFP) study, and the Alan Turing Institute. The DFP pilot study provided the data and the DPUK Data Portal was the means to work with it. Professor Terry Lyons (UOXF Department of Mathematics) is a leading mathematician with innovative contributions to the analysis of multimodal streamed data and methods that have been applied successfully in mental health contexts. He is also a Turing Fellow. With Dr Andrey Kormilitzin (UOXF), he helped to bring the event to fruition.
Collaborator Contribution The Alan Turing Institute hosted and organised the event, and, as the national institute for data science in the UK, was an ideal partner to bring big data specialists to the great challenges in dementia research. Working with the Alan Turing Institute helped to emphasise one of DPUK's core areas of focus: dementia is not just a challenge that psychiatrists or cognitive neuroscientists can solve alone. Data scientists have a hugely important role to play now that we have the data and the DPUK technology available.
Impact The datathon attracted analysts of all stripes, many of whom had not worked with dementia cohort datasets before. Most of the participants were genuinely excited about the data, datathon and the presentations. We are planning on follow up events, perhaps more focussed on each data type at a time. We're hoping to create a community of experts in these particular data and applications of innovative data science methods for Alzheimer's research. This project brings together several modes of information for people with dementia and will likely play a critical role in understanding how to contrast and compare the different perspectives provided by different types of data.
Start Year 2018
 
Description BRACE 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution advice and training on genomic data analysis
Collaborator Contribution Investigating the genetic overlap between AD and other diseases or traits using polygenic risk scores in Avon Longitudinal Study of Parents and Children (ALSPAC)
Impact 1. Application of newly developed methodology (MR-Base), which hallows to do rapid high-throughput analysis of potentially interesting traits and environmental exposures. 2. Test for shared genetic susceptibility between AD and early life lipid levels, glycaemic, anthropometric, behavioral and cognitive traits in ALSPAC children
Start Year 2016
 
Description Bekhterev Research Medical Center for Psychiatry and Neurology 
Organisation St.Petersburg V.M.Bekhterev Psychoneurological Research Institute
Country Russian Federation 
Sector Public 
PI Contribution We provide expertise for genetic data analyses
Collaborator Contribution Genetic data of individuals of Russian ancestry is provided to us by the collaborators.
Impact This is a multidisciplinary collaboration, involves clinicians, bioinformaticians and biologists.
Start Year 2019
 
Description BioFIND - JPND 
Organisation EU Joint Programme - Neurodegenerative Disease Research (JPND)
Country European Union (EU) 
Sector Public 
PI Contribution We led the JPND award on the use of MEG in harmonisation and standarisation for Dementia research, bringing together Pharma and Academic partners from ten sites.
Collaborator Contribution Expertise, knowledge sharing, and scoping of future project needs.
Impact A project initiation report is submitted. A new data sharing project has begun across six sites.
Start Year 2016
 
Description CLEAR-Huntington's Disease 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of MEG-related methods and analysis advice (postdocs involved: Dr Laura Hughes and Dr Ece Kocagoncu).
Collaborator Contribution N/A
Impact Cambridge and UCL collaboration only.
Start Year 2019
 
Description Cambridge 7T consortium 
Organisation Medical Research Council (MRC)
Department MRC Cognition and Brain Sciences Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Forming the new University-MRC partnership and Cambridge 7T consortium. Full access to new facility for both partners.
Collaborator Contribution Staff allocation for physics support and adjunctive technologies for participant interaction.
Impact Multidisciplinary - dementia, neurology, psychiatry, development and ageing, cognitive neuroscience and physics. New head of 7T department has been recruited.
Start Year 2015
 
Description Collaboration with Dr Ece Kocagoncu for NTAD (Dr A Jafarian) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on data analysis of test-retest data from NTAD.
Collaborator Contribution Availability of NTAD data.
Impact Title: Test-reTest reliability of dynamic casual modelling of resting states MEG data of Alzheimer patients.
Start Year 2022
 
Description Collaboration with Eisai AiM Institute 
Organisation Eisai Ltd
Department Eisai Inc
Country United States 
Sector Private 
PI Contribution Consultancy on Polygenic risk score for clinical trials
Collaborator Contribution We are in the process of negotiations
Impact potentially this collaboration will pay for a time of a postdoctoral researcher
Start Year 2018
 
Description Collaboration with European Bioinformatics institute 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution We plan to provide a software for polygenic risk score calculation and prosess the GWAS summary statistics for all current GWASes available in EBI GWAS catalogue
Collaborator Contribution provide data access to the GWAS catalogue
Impact This collaboration will provide the GWAS processed data to the research community for quick and efficient calculation of polygenic risk score for any disorder (stored in the EBI GWAS catalogue)
Start Year 2019
 
Description Collaboration with Prof. Giuseppe Baselli, Department of Electronics, Information and Bioengineering 
Organisation Polytechnic University of Milan
Country Italy 
Sector Academic/University 
PI Contribution I hosted two students from Prof. Baselli's group (Valentina Bordin and Ilaria Bertani) for their MSc thesis and trained them in neuroimaging analysis methods.
Collaborator Contribution The students contributed to the project (DPUK - Discovery Award 2018 - PI: Ludovica Griffanti) by performing data analysis, presenting a conference poster and writing a journal article.
Impact The collaboration resulted in a poster presentation at the organisation for human brain mapping (OHBM) conference. Title: "Harmonising measures of white matter hyperintensities across sites and studies: impact of training and manual rating in FSL-BIANCA". The scientific journal article is available as preprint and currently under peer-review. Valentina Bordin has ben awarded with a scholarship to fund a PhD in biomedical engineering. Thanks to the skills learnt as part of this project, she is planning focus on assessing the utility of MRI as a marker for evaluating the efficacy of tele-rehabilitation in dementia.
Start Year 2018
 
Description Collaboration with Professor Francesco Sardanelli, Dept. of Radiology University of Milan, IRCCS Policlinico San Donato 
Organisation IRCCS Policlinico San Donato
Country Italy 
Sector Hospitals 
PI Contribution I hosted a PhD student from Prof. Sardanelli's group (Dr. Luca Melazzini) and trained him in neuroimaging analysis methods.
Collaborator Contribution The student contributed to the project (DPUK - Discovery Award 2018 - PI: Ludovica Griffanti) by performing data analysis and interpretation, submitting a conference poster and writing a journal article.
Impact The collaboration resulted in an abstract accepted as oral presentation at the European Congress of Radiology (ECR) 2020. "Classifying white matter hyperintensities according to intensity and spatial localisation reveals specific association with cognition". The scientific journal article is under review. Dr. Melazzini submitted his PhD thesis (including work part of this collaboration) and will defend in March 2021.
Start Year 2019
 
Description Collaboration with Professor Francesco Sardanelli, Dept. of Radiology University of Milan, IRCCS Policlinico San Donato 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution I hosted a PhD student from Prof. Sardanelli's group (Dr. Luca Melazzini) and trained him in neuroimaging analysis methods.
Collaborator Contribution The student contributed to the project (DPUK - Discovery Award 2018 - PI: Ludovica Griffanti) by performing data analysis and interpretation, submitting a conference poster and writing a journal article.
Impact The collaboration resulted in an abstract accepted as oral presentation at the European Congress of Radiology (ECR) 2020. "Classifying white matter hyperintensities according to intensity and spatial localisation reveals specific association with cognition". The scientific journal article is under review. Dr. Melazzini submitted his PhD thesis (including work part of this collaboration) and will defend in March 2021.
Start Year 2019
 
Description Covid19 Neuroscience Group @7T 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution New program of research into acute and chronic effects of COVID19 on the brain, including respiratory, cognitive and mental health effects Data collection of inpatients, and those recovering, from severe COVID19, and innovations in brain stem neurochemical imaging
Collaborator Contribution Expertise in spectroscopy and respiratory control from the brain Expertise in remote cognitive testing and normative data
Impact Pending publications Conference papers accepted, ISMRN, BNA
Start Year 2020
 
Description Covid19 Neuroscience Group @7T 
Organisation University of Oxford
Department Oxford Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution New program of research into acute and chronic effects of COVID19 on the brain, including respiratory, cognitive and mental health effects Data collection of inpatients, and those recovering, from severe COVID19, and innovations in brain stem neurochemical imaging
Collaborator Contribution Expertise in spectroscopy and respiratory control from the brain Expertise in remote cognitive testing and normative data
Impact Pending publications Conference papers accepted, ISMRN, BNA
Start Year 2020
 
Description DDI and DPUK 
Organisation Alzheimer's Research UK
Department UCL Drug Discovery Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution - JG suggested to introduce the two platforms in turn to gain a better idea of the focuses of each. Given that DPUK funding has been renewed for a further five years from July 2020, it was suggested to discuss 'DPUK2' as opposed to the current scientific programme in place. - The DPUK2 Data Portal and Informatics theme will continue into DPUK2. A manuscript describing the Data Portal has been published today on the European Journal of Epidemiology website. The Data Portal provides secure remote access to unprecedented volume and depths of data, hosting 42 population cohort studies and millions of individuals' anonymised information. - DPUK2 will also been involved in precision recruitment to trials through the Trial Delivery Framework - a structure which will allow highly targeted, richly phenoyped, risk-stratified populations to be consented for re-contact to Experimental Medicine (EM) studies. The Trials Delivery Framework aims to support centres to serve wider recruitment to early phase trials (eg Phase 0 to 1b, rather than later), but does not propose completely reinventing current systems - it will be aligning what is already in place and improving their efficiency. - The EM incubator theme in DPUK2 capitalises on the private public partnership success within DPUK1 - it is a cross-industry pool of companies and academics in a pre-competitive space. The focus of the EM Incubator is largely on human trials, asking questions on how we can best validate targets for humans. - DPUK2 industrial partners are highly supportive of the collaborative environment of the platform, enabling them to achieve understanding early on how companies can best move into drug development and use. - Therefore DPUK2 as a whole has an overall focus on translation and experimental studies. The platform would like to put these services to DDI and gain a better understanding on how DPUK can, for example, support discovery molecules being passed on to other entities.
Collaborator Contribution - Please see PowerPoint slide deck '200424 DDA slides for DPUK' for reference - JD described the network of the three DDIs (Oxford, Cambridge, UCL), which overall primarily focus on drug design, synthesis, target ID and validation - screening through to an in vivo Proof of Concept (POC) end point. The institutes sit between academia and industry, with the DDIs often reflecting the interests of the researchers involved. The network aims to take early targets and 'de-risk' them, ahead of passing to industry to develop the drugs further. - The lead molecules isolated by the DDIs are not clinical candidates - it could be up two years of further funding before a reasonable clinical candidate is obtained. However, the DDI network needs to think about translation into humans from the beginning, given that is the target's ultimate aim. - Indeed, although the DDI focuses on producing an in vivo POC endpoint, it is has been clear from the past few years that industrial partners are increasingly looking for the network to provide a blueprint of how these targets can translate into clinic. - The Cambridge DDI has a key focus on proteostasis, with some neuroimmune, neuronal health and vascular research. - The Oxford DDI focuses mostly on neuroimmunity and Alzheimer's Disease, due to the disease's strong genetic component to inform target design. There is also research into organelle dysfunction (mostly in Parkinson's) and some target classes (ligases, kinases etc) - The UCL DDI interests focus on microglia, astrocytes and synaptic health, and takes part in opportunistic research on vascular, mitophagy and b-amyloid questions. A spin-out involving astrocytes (Astronautics) has been successful. There is a strong crossover of research with the Oxford DDI.
Impact - Potential opportunities for collaboration between DDI and DPUK include: - Translational biomarkers ? Target engagement ? Proof of mechanism - Experimental medicine for novel mechanisms - Patient stratification (for novel mechanisms) - Human data to support novel target ID & validation
Start Year 2020
 
Description DPUK 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Public 
PI Contribution Steering Group member, DPUK work package lead.
Collaborator Contribution Creating Dementia Platform UK Data Portal
Impact In the process of creating on-line database with dementia cohorts, available in the UK and pipelines for data analyses. Multidisceplinary: genetics, bioinfirmatics, IT.
Start Year 2014
 
Description DPUK Cambridge 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Optimisation of high-content imaging protocols with Opera Phenix imager
Collaborator Contribution The ARUK Stem Cell Research Centre, Cambridge has standardised the use of the Opera Phenix and Nanostring Sprint instruments for QC in iPSC reprogramming and cproduction of cortical neurons. The Phenix is used for high-throughput imaging of pluripotency markers in patient-derived lines that are generated at the centre. The lab has established a method for routine characterisation of cortical neuron productions using the Nanostring digital gene expression platform. This will facilitate harmonisation of protocols between DPUK centres, and within the STEMBANCC consortium. The imaging platform has been used to develop methods for production of human microglia from iPSCs, and to study cell biology in patient iPSC-derived microglia, focussing on TREM2 mutatiosn. In collaboration with Talisman Therapeutics and AstraZeneca, assays have been established to measure protein uptake in cortical neurons by live imaging.
Impact Development of a strong Dementia Stem Cell Network in DPUK
Start Year 2016
 
Description DPUK DSCN 
Organisation Cardiff University
Department School of Biosciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Forming DPUK Dementia Stem Cell Network
Collaborator Contribution Forming DPUK Dementia Stem Cell Network
Impact Collaborations and interactions
Start Year 2015
 
Description DPUK DSCN 
Organisation University College London
Department Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution Forming DPUK Dementia Stem Cell Network
Collaborator Contribution Forming DPUK Dementia Stem Cell Network
Impact Collaborations and interactions
Start Year 2015
 
Description DPUK DSCN 
Organisation University of Cambridge
Department Gurdon Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Forming DPUK Dementia Stem Cell Network
Collaborator Contribution Forming DPUK Dementia Stem Cell Network
Impact Collaborations and interactions
Start Year 2015
 
Description DPUK DSCN 
Organisation University of Edinburgh
Department MRC Centre for Regenerative Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Forming DPUK Dementia Stem Cell Network
Collaborator Contribution Forming DPUK Dementia Stem Cell Network
Impact Collaborations and interactions
Start Year 2015
 
Description DPUK DSCN 
Organisation University of Manchester
Department Manchester Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution Forming DPUK Dementia Stem Cell Network
Collaborator Contribution Forming DPUK Dementia Stem Cell Network
Impact Collaborations and interactions
Start Year 2015
 
Description DPUK Data Discovery Tools Categorisation and Coding Programme 
Organisation University of Oxford
Department Department of Psychiatry
Country United Kingdom 
Sector Academic/University 
PI Contribution Provide data from our cohort
Collaborator Contribution Create Data discovery tool
Impact Still ongoing
Start Year 2018
 
Description DPUK Imaging Consortium 
Organisation MRC Dementias Platform UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Sharing of Imaging protocols and data management structures
Collaborator Contribution N/A
Impact Project recently commenced
Start Year 2016
 
Description DPUK Tau Partnership 
Organisation Life Molecular Imaging
Country Germany 
Sector Private 
PI Contribution The partnership involves the use of a novel PET tracer (PI2620) developed by Life Molecular Imaging to carry out Tau PET imaging in existing DPUK cohorts (specifically, the PREVENT AD cohort and the AMYPAD PNHS cohort)
Collaborator Contribution LMI (part of the Alliance Medical Group) brings industry expertise in molecular imaging of degenerative brain disease to the Tau-PET study. This study will benefit from a key investigational compound used for PET imaging which is being developed by LMI.
Impact Collaboration between industry and DPUK (Neurology, Radiology, Nuclear MedicineEpidemiology, Psychiatry).
Start Year 2019
 
Description DPUK industry partnership 
Organisation Araclon Biotech
Country Spain 
Sector Private 
PI Contribution The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia
Collaborator Contribution Expertise and technologies
Impact Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673
Start Year 2014
 
Description DPUK industry partnership 
Organisation AstraZeneca
Department MedImmune
Country United Kingdom 
Sector Private 
PI Contribution The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia
Collaborator Contribution Expertise and technologies
Impact Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673
Start Year 2014
 
Description DPUK industry partnership 
Organisation GlaxoSmithKline (GSK)
Department Neurology and GI Centre of Excellence for Drug Discovery (CEDD) GSK
Country United Kingdom 
Sector Private 
PI Contribution The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia
Collaborator Contribution Expertise and technologies
Impact Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673
Start Year 2014
 
Description DPUK industry partnership 
Organisation Ixico
Country United Kingdom 
Sector Private 
PI Contribution The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia
Collaborator Contribution Expertise and technologies
Impact Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673
Start Year 2014
 
Description DPUK industry partnership 
Organisation Janssen Research & Development
Country Global 
Sector Private 
PI Contribution The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia
Collaborator Contribution Expertise and technologies
Impact Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673
Start Year 2014
 
Description DPUK industry partnership 
Organisation SomaLogic
Country United States 
Sector Private 
PI Contribution The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia
Collaborator Contribution Expertise and technologies
Impact Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673
Start Year 2014
 
Description DPUK-2 (2020 - 2023) 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Calculation of pathway specific PRS, relevant to the Neuroinflammation work package.
Collaborator Contribution Access to the DPUK cohorts
Impact data access to DPUK cohorts
Start Year 2020
 
Description DSG (Data Study Group) Network 
Organisation Alan Turing Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution A joint collaboration with the Turing Institue for using the DPUK Data Portal for Workshop - Machine learning - Data Portal infrastructure across DPUK population cohorts.
Collaborator Contribution Provision of the data workshop infrastructure - DPUK Data Portal and joint hosting of workshop
Impact Newly active March 2019
Start Year 2019
 
Description DSG (Data Study Group) Network 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution A joint collaboration with the Turing Institue for using the DPUK Data Portal for Workshop - Machine learning - Data Portal infrastructure across DPUK population cohorts.
Collaborator Contribution Provision of the data workshop infrastructure - DPUK Data Portal and joint hosting of workshop
Impact Newly active March 2019
Start Year 2019
 
Description Dementias Platform Europe - a collaboration between EMIF-AD and DPUK 
Organisation European Medical Information Framework (EMIF)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution John Gallacher and consultant Prof Derek Hill (advisor to the DPUK1 Executive Team) met with Prof PJ Visser (PI of EMIF) to investigate the possibility of a merger of the two platforms' data and technology, with the support from industry.
Collaborator Contribution Prof Visser hosted the 2-day visit in Amsterdam, providing a tour and in-depth analysis of the runnings and technical features of the EMIF platform.
Impact Prof Derek Hill provided a written report to internal DPUK colleagues on the potential strengths and challenges of merging with EMIF. Industry partners have shown interest in supporting the scheme with funding, with further meetings due to happen in February 2020 to move the initiative forward.
Start Year 2019
 
Description Dementias Platform UK Stem Cell Partnership 
Organisation MRC Dementias Platform UK
Country United Kingdom 
Sector Academic/University 
PI Contribution OPDC will share expertise and stem cell lines as part of DPUK Stem Cell Network
Collaborator Contribution Members will share expertise and stem cell lines as part of DPUK Stem Cell Network
Impact Ongoing
Start Year 2016
 
Description Dementias Platform UK Stem Cell Partnership 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution OPDC will share expertise and stem cell lines as part of DPUK Stem Cell Network
Collaborator Contribution Members will share expertise and stem cell lines as part of DPUK Stem Cell Network
Impact Ongoing
Start Year 2016
 
Description Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease 
Organisation McGill University
Department Montreal Neurological Institute and Hospital
Country Canada 
Sector Hospitals 
PI Contribution Laura Parkkinen and team will analyze CSF samples
Collaborator Contribution Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients.
Impact We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019
Start Year 2018
 
Description Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Laura Parkkinen and team will analyze CSF samples
Collaborator Contribution Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients.
Impact We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019
Start Year 2018
 
Description Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease 
Organisation University of Barcelona
Country Spain 
Sector Academic/University 
PI Contribution Laura Parkkinen and team will analyze CSF samples
Collaborator Contribution Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients.
Impact We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019
Start Year 2018
 
Description Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease 
Organisation University of Bologna
Department Department of Neurologial Sciences
Country Italy 
Sector Academic/University 
PI Contribution Laura Parkkinen and team will analyze CSF samples
Collaborator Contribution Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients.
Impact We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019
Start Year 2018
 
Description Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease 
Organisation University of Göttingen
Country Germany 
Sector Academic/University 
PI Contribution Laura Parkkinen and team will analyze CSF samples
Collaborator Contribution Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients.
Impact We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019
Start Year 2018
 
Description Dr Ben Vallin with Prof Caleb Webber 
Organisation UK Dementia Research Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Collaborative work with the Caleb Webber's group in Cardiff (and which involves the flow cytometry facility of the MRC Weatherall Institute of Molecular Medicine). We designed a cellular model of ?-synuclein propagation composed of dopaminergic neurons derived from healthy control iPSCs co-cultured with dopaminergic neurons derived from Parkinson's disease (PD) iPSCs harbouring a triplication of the ?-synuclein locus. I performed the cell culture, isolated the viable dopaminergic neurons and provided them to the group of Caleb Webber for single cell RNA-sequencing.
Collaborator Contribution Caleb Webber's team separated the cell samples we provided into single cells and they are currently generating the corresponding cDNA library for single cell RNA-sequencing and bioinformatic analysis.
Impact n/a
Start Year 2021
 
Description Dr Brent Ryan & Derek Narendra NIH Inherited Movement Disorders Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD 
Organisation National Institutes of Health (NIH)
Department National Institute of Neurological Disorders and Stroke (NINDS)
Country United States 
Sector Public 
PI Contribution Dr Brent Ryan & Derek Narendra NIH Inherited Movement Disorders Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD. Scope: Collaboration to assess mitophagy in models of PD
Collaborator Contribution Dr Brent Ryan & Derek Narendra NIH Inherited Movement Disorders Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD. Scope: Collaboration to assess mitophagy in models of PD Publication: Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Trends Biochem Sci. 2020 Dec 12:S0968-0004(20)30278-4. doi: 10.1016/j.tibs.2020.11.007. Online ahead of print. PMID: 33323315
Impact Publication: Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Trends Biochem Sci. 2020 Dec 12:S0968-0004(20)30278-4. doi: 10.1016/j.tibs.2020.11.007. Online ahead of print. PMID: 33323315
Start Year 2020
 
Description Dr Brent Ryan & Evandro Fang University of Oslo, Norway Scope: Assessment of mitophagy modulators in iPSC models of PD 
Organisation University of Oslo
Country Norway 
Sector Academic/University 
PI Contribution Dr Brent Ryan collaborating with Evandro Fang University of Oslo, Norway Scope: Assessment of mitophagy modulators in iPSC models of PD Output: Aman Y, Ryan B, Torsetnes SB, Knapskog AB, Watne LO, McEwan WA, Fang EF. Int Rev Neurobiol. 2020;155:169-202. doi: 10.1016/bs.irn.2020.02.008. Epub 2020 Aug 11. PMID: 32854854
Collaborator Contribution Dr Brent Ryan collaborating with Evandro Fang University of Oslo, Norway Scope: Assessment of mitophagy modulators in iPSC models of PD Output: Aman Y, Ryan B, Torsetnes SB, Knapskog AB, Watne LO, McEwan WA, Fang EF. Int Rev Neurobiol. 2020;155:169-202. doi: 10.1016/bs.irn.2020.02.008. Epub 2020 Aug 11. PMID: 32854854
Impact Publication: Aman Y, Ryan B, Torsetnes SB, Knapskog AB, Watne LO, McEwan WA, Fang EF. Int Rev Neurobiol. 2020;155:169-202. doi: 10.1016/bs.irn.2020.02.008. Epub 2020 Aug 11. PMID: 32854854
Start Year 2020
 
Description Dr Brent Ryan collaboration with Dr Maria Letizia Lo Faro NDSS 
Organisation University of Oxford
Department Nuffield Department of Surgical Sciences Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Dr Maria Letizia Lo Faro (NDSS) to investigate the role of mitophagy in models of organ transplantation initiated in 2022. Grants pending.
Collaborator Contribution Collaboration with Dr Maria Letizia Lo Faro (NDSS) to investigate the role of mitophagy in models of organ transplantation initiated in 2022. Grants pending.
Impact Collaboration with Dr Maria Letizia Lo Faro (NDSS) to investigate the role of mitophagy in models of organ transplantation initiated in 2022. Grants pending.
Start Year 2022
 
Description Dr Brent Ryan collaboration with Dr Mark Cookson 
Organisation National Institute on Aging
Department Laboratory of Neurogenetics
Country United States 
Sector Public 
PI Contribution Collaboration with Dr Mark Cookson (National Institute on Aging, USA) initiated in 2022 to share proteomics datasets from patient iPSC-derived cell types including dopaminergic neurons and microglia. Not governed by formal agreements (grants pending).
Collaborator Contribution Collaboration with Dr Mark Cookson (National Institute on Aging, USA) initiated in 2022 to share proteomics datasets from patient iPSC-derived cell types including dopaminergic neurons and microglia. Not governed by formal agreements (grants pending).
Impact n/a
Start Year 2022
 
Description Dr Brent Ryan collaboration with Dr Morten Meyer (University of Southern Denmark). 
Organisation University of Southern Denmark
Country Denmark 
Sector Academic/University 
PI Contribution Collaboration with Dr Morten Meyer (University of Southern Denmark). Investigation of RhoA signalling in Parkinson's- student Sissel Ida Schmidt is visiting for 6 months. Publication Okarmus et al 2021.
Collaborator Contribution Investigation of RhoA signalling in Parkinson's- student Sissel Ida Schmidt is visiting for 6 months. Publication Okarmus et al 2021.
Impact Justyna Okarmus, Jesper F. Havelund, Matias Ryding, Sissel I. Schmidt, Helle Bogetofte, Rachel Heon-Roberts, Richard Wade-Martins, Sally A. Cowley, Brent J. Ryan, Nils J. Færgeman, Poul Hyttel, Morten Meyer, Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism, Stem Cell Reports, Volume 16, Issue 6, 2021, Pages 1510-1526, ISSN 2213-6711, https://doi.org/10.1016/j.stemcr.2021.04.022. (https://www.sciencedirect.com/science/article/pii/S2213671121002174) Abstract: Summary PARK2 (parkin) mutations cause early-onset Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that participates in several cellular functions, including mitochondrial homeostasis. However, the specific metabolomic changes caused by parkin depletion remain unknown. Here, we used isogenic human induced pluripotent stem cells (iPSCs) with and without PARK2 knockout (KO) to investigate the effect of parkin loss of function by comparative metabolomics supplemented with ultrastructural and functional analyses. PARK2 KO neurons displayed increased tricarboxylic acid (TCA) cycle activity, perturbed mitochondrial ultrastructure, ATP depletion, and dysregulation of glycolysis and carnitine metabolism. These perturbations were combined with increased oxidative stress and a decreased anti-oxidative response. Key findings for PARK2 KO cells were confirmed using patient-specific iPSC-derived neurons. Overall, our data describe a unique metabolomic profile associated with parkin dysfunction and show that combining metabolomics with an iPSC-derived dopaminergic neuronal model of PD is a valuable approach to obtain novel insight into the disease pathogenesis. Keywords: Parkinson's disease; parkin; induced pluripotent stem cells; metabolomics; mitochondria; oxidative stress
Start Year 2021
 
Description Dr Brent Ryan collaboration with Prof. Martin Rossel Larsen & Dr Helle Bogetofte (University of Southern Denmark) 
Organisation University of Southern Denmark
Country Denmark 
Sector Academic/University 
PI Contribution Collaboration with Prof. Martin Rossel Larsen & Dr Helle Bogetofte (University of Southern Denmark) to perform post-translational proteomics on iPSC-derived neurons generated in Oxford. Not governed by formal agreements (grants pending).
Collaborator Contribution Continuing collaboration with Prof. Martin Rossel Larsen & Dr Helle Bogetofte (University of Southern Denmark) to perform post-translational proteomics on iPSC-derived neurons generated in Oxford. Not governed by formal agreements (grants pending).
Impact n/a
Start Year 2021
 
Description EISAI 
Organisation Eisai Ltd
Department Eisai Europe Ltd
Country United Kingdom 
Sector Private 
PI Contribution we provide expertise and data analysis of pathways and gene networks related to neurodegeneration
Collaborator Contribution The partner provide expertise the the biological definition of neurodegenerative gene networks
Impact NA
Start Year 2019
 
Description EMIF-AD and DPUK 
Organisation European Medical Information Framework (EMIF)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution Towards DP Europe: What do we want to achieve? Components and technical aspects COMPONENTS v Catalogue • How to integrate DPUK/EMIF Catalogues? • How to implement direct link to dataset if data are stored on platform? v Subject level data platform with data analysis functions Towards DP Europe: What do we want to achieve? Management, funding & future expansions MANAGEMENT v Interaction cohort owners: UK/Europe/Worldwide v Upload cohort data v Harmonization v Managing data requests v MTA/contracting FUNDING v DP UK v DP Europe (Pharma) FUTURE EXPANSIONS v Human Brain Project Medical Informatic platform v GAAIN • DPUK • DP Europe instance (to be hosted outside UK in Europe) v Platform for harmonized subject-level data on tranSMART v Prepad/Switchbox like access to local database v Common Ontology • Which variables to harmonize? TECHNICAL ASPECTS v Integration v Hosting v Maintenance
Collaborator Contribution Towards DP Europe: What do we want to achieve? Components and technical aspects COMPONENTS v Catalogue • How to integrate DPUK/EMIF Catalogues? • How to implement direct link to dataset if data are stored on platform? v Subject level data platform with data analysis functions Towards DP Europe: What do we want to achieve? Management, funding & future expansions MANAGEMENT v Interaction cohort owners: UK/Europe/Worldwide v Upload cohort data v Harmonization v Managing data requests v MTA/contracting FUNDING v DP UK v DP Europe (Pharma) FUTURE EXPANSIONS v Human Brain Project Medical Informatic platform v GAAIN
Impact Future plans and discussions surrounding the establishment of DPEU.
Start Year 2020
 
Description ENIGMA MEG working group 
Organisation University of Southern California
Country United States 
Sector Academic/University 
PI Contribution Supply of a dementia and healthy participants dataset.
Collaborator Contribution TBC
Impact A new collaboration in development, initiated late 2020 and the first meeting took place in January 2021.
Start Year 2021
 
Description ETH Zurich - Oxford collaboration for functional imaging in a rodent model of Parkinson's disease 
Organisation ETH Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Richard Wade-Martin's lab has engineered the rodent model of Parkinson's disease (human SCA overexpression). This model has been characterized with histology, voltammetry of dopamine release in cell culture, and behaviourally. In collaboration with the Zurich group, Johannes Klein has performed data analysis on the imaging provided by ETH Zurich.
Collaborator Contribution Oxford does not currently have the ability to perform high-quality resting state MRI in small animals. Our collaboration partners at ETH of acquired the imaging data, performed pre-processing with motion correction and ICA data cleaning. Together, we have analysed differences in brain networks between mice overexpressing human alpha-synuclein, and alpha-synuclein knockout siblings.
Impact The research is ongoing. The imaging data will be published in the coming year.
Start Year 2015
 
Description Enhancing autophagy flux in Parkinson's disease 
Organisation AstraZeneca
Department Astra Zeneca
Country United States 
Sector Private 
PI Contribution OPDC test drug like molecules in cellular models of Parkinson's
Collaborator Contribution Astra Zeneca to provide drug-like small molecules.
Impact Ongoing
Start Year 2016
 
Description Established collaboration with Ira Milosevic, University of Oxford Wellcome Centre for Human Genetics 
Organisation University of Oxford
Department Wellcome Trust Centre for Human Genetics
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution To study synaptic vesicle recycling and STXBP6 biology in our Parkinson's models. Ira will provide the tools and expertise.
Collaborator Contribution The collaboration will be to study synaptic vesicle recycling and STXBP6 biology in our Parkinson's models. Ira will provide tools and expertise
Impact The collaboration will be to study synaptic vesicle recycling and STXBP6 biology in our Parkinson's models. Ira will provide tools and expertise
Start Year 2021
 
Description European Prevention of Alzheimers disease project (EPAD) 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution DPUK is contributing towards the trials infrastructure and recruitment tot he EPAD longitudinal cohort study
Collaborator Contribution European colleagues are also contributing towards the trials infrastructure and recruitment tot he EPAD longitudinal cohort study
Impact Multi-disciplinary: clinicians, imagers, geneticists, statisticians, epidemiologists.
Start Year 2016
 
Description Evaluation of selected CSF proteins as prognostic markers of dementia in patients with Parkinson's disease 
Organisation Oxford University Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of samples from our cohort
Collaborator Contribution Measuring two serum proteins (haptoglobin and homocysteine), as well as two cerebrospinal fluid proteins (Aß1-42 and phospho-tau).
Impact Ongoing research
Start Year 2016
 
Description Free living walking behaviour in a cohort of people with RBD 
Organisation Newcastle University
Department Institute of Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution applying the Axivity Device to RBD and Control participants attending Discovery clinic and providing clinical data
Collaborator Contribution Further analysis of data to look for evidence of the onset of motor-symptoms.
Impact Ongoing research
Start Year 2016
 
Description GENFI study - multi centre study 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution NA
Impact NA
Start Year 2016
 
Description GR@CE 
Organisation Catalan Health Institute (ICS)
Country Spain 
Sector Public 
PI Contribution we analyse the genome-wide data
Collaborator Contribution the collaborators provided the data to us
Impact it is a multidisciplinary collaboration, involve clinicians, biologists and bioinformaticians
Start Year 2020
 
Description GW4 fellowship 
Organisation Cardiff University
Department Brain Research Imaging Centre (CUBRIC)
Country United Kingdom 
Sector Academic/University 
PI Contribution co-supervisor; advice and training on genomic data analysis
Collaborator Contribution A researcher, Judith Harrison
Impact To explore disease pathways in Alzheimer's disease using MRI Biomarkers and Polygenic Scores
Start Year 2017
 
Description GWAIS 
Organisation University of Liege
Country Belgium 
Sector Academic/University 
PI Contribution We bring our expertise in AI and ML
Collaborator Contribution Collaborators bring their expertise in genetic interaction analyses.
Impact It is a multidisciplinary collaboration involving mathematicians, software developers and bioinformaticians
Start Year 2021
 
Description Gothenberg CSF projects 
Organisation University of Gothenburg
Country Sweden 
Sector Academic/University 
PI Contribution Sharing of samples
Collaborator Contribution Assays
Impact A number of papers and also training of laboratory staff
Start Year 2012
 
Description Harvard University 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution generation of polygenic risk scores
Collaborator Contribution provision of tissue samples and genotyped data
Impact none yet
Start Year 2019
 
Description Hong Kong University of Science and Technology 
Organisation The Hong Kong University of Science and Technology
Country Hong Kong 
Sector Academic/University 
PI Contribution Then HKUST will provide the summary statistics from the previous publication work (DOI: 10.1073/pnas.1715554115) to Cardiff to test if models derived from the Chinese population data can be used for disease classification in the European-descent population.
Collaborator Contribution The Cardiff will provide the models derived from the European population, and HKUST will help to examine if those models can classify AD in the Chinese population.
Impact NA
Start Year 2022
 
Description Innovate UK 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Consultancy
Collaborator Contribution Design of Alzhemer's disease chip
Impact In the process of designing of Alzhemer's disease SNP array. Multidisceplinary: medical genetics, bioinformatics, statistics
Start Year 2015
 
Description Insight 46 
Organisation Medical Research Council (MRC)
Department MRC Cognition and Brain Sciences Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaborating with colleagues at the UCL MRC National Survey for Health and Development, Institute of Molecular Neuroscience, and Institute of Nuclear Medicine, Insight 46 is a major prospective two-time point (0, 12m) MRI, amyloid PET, clinical, biomarker and neuropsychological study of 500 members of the MRC National Survey for Health and Development 1946 birth cohort. This highly inter-disciplinary study involving UCL based epidemiologists, neurologists, imagers, clinical chemists, geneticists and statisticians aims to determine the earliest biomarker changes of AD, the contribution of genetic and life course influences on the development of late life cognitive impairment, and the optimal means of designing AD prevention studies. This >£5M project includes funding from ARUK, MRC Dementias Platform UK (WP4), Wolfson Foundation and Brain Research Trust, as well as industry contributions (~£850K, Eli Lilly). As well as coordinating the project (with Fox, Richards) I supervise a study manager, two clinical PhD students (Lane and Parker, a Wellcome Training Fellowship), and a study coordinator. The study is well underway, with >300 scaned; cross-sectional data will complete in October 2017; and longitudinal collection two years later.
Collaborator Contribution N/A
Impact N/A
Start Year 2014
 
Description International Parkinson's Disease genetic Consortium (IPDGC) 
Organisation The International Parkinson Disease Genomics Consortium
Sector Academic/University 
PI Contribution New collaboration with the International Parkinson's Disease genetic Consortium (IPDGC); single-cell RNA seq studies, spatial transcriptomics, next generation pathology (i.e. developing deep learning algorithms for PD-related pathologies)
Collaborator Contribution New collaboration with the International Parkinson's Disease genetic Consortium (IPDGC); single-cell RNA seq studies, spatial transcriptomics, next generation pathology (i.e. developing deep learning algorithms for PD-related pathologies)
Impact New collaboration with the International Parkinson's Disease genetic Consortium (IPDGC); single-cell RNA seq studies, spatial transcriptomics, next generation pathology (i.e. developing deep learning algorithms for PD-related pathologies)
Start Year 2019
 
Description JPND 
Organisation JPND Research
Country Global 
Sector Academic/University 
PI Contribution Joint grant funding and projects
Collaborator Contribution Working with collaborative members on research activities
Impact no
Start Year 2016
 
Description JPND EUFIND - European Ultrahigh Field Imaging Biomarkers for Dementia 
Organisation EU Joint Programme - Neurodegenerative Disease Research (JPND)
Country European Union (EU) 
Sector Public 
PI Contribution An international consortium for harmonisation and standardisation of UHF-MRI for Dementia Research. We have contributed expertise, data, and engaged in a pilot study for feasibility and methods development
Collaborator Contribution An international consortium for harmonisation and standardisation of UHF-MRI for Dementia Research. Our partners from 20 EU sites have contributed expertise, data, and engaged in a pilot study for feasibility and methods development
Impact A project initiation report is submitted to JPND
Start Year 2016
 
Description Janssen NV Funding Uplift 2018/19 
Organisation Johnson & Johnson
Department Janssen Pharmaceutica
Country Global 
Sector Private 
PI Contribution DPUK Oxford provide project management and financial management for projects supported as part of this partnership
Collaborator Contribution As well as supporting the project through financial contributions Janssen are actively involved in collaborative research associated with DPUK projects.
Impact Publications arising will be reported by project leads
Start Year 2014
 
Description Leuven University 
Organisation University of Leuven
Country Belgium 
Sector Academic/University 
PI Contribution generation of polygenic risk scores
Collaborator Contribution sharing genotyped data and PRS
Impact none yet
Start Year 2018
 
Description Lysosomal dysfunction and glycosphingolipid dysregulation in Parkinson's 
Organisation University of Oxford
Department Department of Pharmacology
Country United Kingdom 
Sector Academic/University 
PI Contribution We have provided serum samples from our cohort
Collaborator Contribution analyse serum/plasma and CSF from PD patients, at-­-risk patients and control cases as our aims are to characterise the pattern of expression of GSLs in PD and to search for lipid biomarkers
Impact Ongoing research
Start Year 2016
 
Description MINDMAPS AD UK 
Organisation MRC Dementias Platform UK
Country United Kingdom 
Sector Academic/University 
PI Contribution We are collaborating with Imperial on the Mindmaps project, to combine their UCBJ PET data with our MEG data. The aim is to test the link between synaptic density changes and resting state connectivity in Alzheimer's disease.
Collaborator Contribution Dr Eugenii Rabiner of Invicro, leads MIND MAPS - a collaboration between Invicro, the world's leading neuroscience translational imaging centre, six industry partners (AbbVie, Biogen, Celgene, Hamamatsu Photonics, Pfizer and Takeda) and UK's leading academic centres (King's College, Imperial College, University College, Cambridge, Newcastle). Each partner has contributed their particular expert knowledge. Invicro provided the overall scientific design and cutting edge imaging methodologies, the academic partners contribute disease specific knowledge and expertise in patient selection and care. Industry partners provide the knowledge of promising treatment targets and treatments. The collaboration combines these ingredients to ensure that the techniques being developed and tested by the team are truly fit for purpose to support future disease modifying clinical trials. It demonstrates a collaborative way of working that signposts the future of dementia research.
Impact TBC
Start Year 2017
 
Description MRC fellowship 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution advice and training on genomic data analysis
Collaborator Contribution A researcher, Dr. Emma Anderson, who is a highly productive junior researcher
Impact 1. To improve causal inference in mendelian randomization studies of dementia 2. To improve understanding of the genetic risk for dementia and trajectories of cognitive capabilities in aging 3. To identify modifiable risk factors that are related to dementia and cognitive decline
Start Year 2016
 
Description Misplaced in space 
Organisation University of East Anglia
Country United Kingdom 
Sector Academic/University 
PI Contribution Development of PE concept, and data sharing.
Collaborator Contribution Artistic development of a Dementia outreach exhibition
Impact Exhibition in 2017 at the University of East Anglia
Start Year 2016
 
Description NTAD Collaboration with UCL-UK DRI Plasma Tau Analysis 
Organisation UK Dementia Research Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution NTAD study provides blood samples obtained from participants with Alzheimer's disease.
Collaborator Contribution Collaboration with Dr Henrik Zetterberg & Dr Amanda Heslegrave, UK DRI Fluid Biomarker Laboratory at UCL, for plasma tau analysis obtained from NTAD participants.
Impact TBC
Start Year 2020
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Alzheimer's Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation AstraZeneca
Department Astra Zeneca
Country United States 
Sector Private 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Eli Lilly & Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Johnson & Johnson
Department Janssen Pharmaceuticals
Country United States 
Sector Private 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Oxford University Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Academic/University 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description National Institutes of Health Oxford-Cambridge Scholars Programme (NIH-OxCam) for Stewart Humble 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution NIH OxCam programme, a doctoral training programme for medical students to continue their education in biomedical research at either Oxford or Cambridge University in partnership with the National Institutes of Health (NIH) in Washington DC. (PI: Michael Ward, NIH; Co-supervisor: Wade-Martins; 01/10/16-30/09/20) Molecular mechanisms of progranulin in FTD
Collaborator Contribution NIH OxCam programme, a doctoral training programme for medical students to continue their education in biomedical research at either Oxford or Cambridge University in partnership with the National Institutes of Health (NIH) in Washington DC. (PI: Michael Ward, NIH; Co-supervisor: Wade-Martins; 01/10/16-30/09/20) Molecular mechanisms of progranulin in FTD
Impact NIH OxCam programme, a doctoral training programme for medical students to continue their education in biomedical research at either Oxford or Cambridge University in partnership with the National Institutes of Health (NIH) in Washington DC. (PI: Michael Ward, NIH; Co-supervisor: Wade-Martins; 01/10/16-30/09/20) Molecular mechanisms of progranulin in FTD
Start Year 2016
 
Description National Taiwan University 
Organisation National Taiwan University
Country Taiwan, Province of China 
Sector Academic/University 
PI Contribution generation of polygenic risk scores
Collaborator Contribution still in negotiations
Impact still in negotiation
Start Year 2020
 
Description Neurochip Task Force Genetics Study 
Organisation German Centre for Neurodegenerative Diseases
Country Germany 
Sector Public 
PI Contribution All study members to genotype their cohort on same chip
Collaborator Contribution Sharing genomic data between cohorts with OPDC and Centre PD
Impact Still active
Start Year 2018
 
Description Neurochip Task Force Genetics Study 
Organisation University of Luxembourg
Department Faculty of Science, Technology and Communication
Country Luxembourg 
Sector Academic/University 
PI Contribution All study members to genotype their cohort on same chip
Collaborator Contribution Sharing genomic data between cohorts with OPDC and Centre PD
Impact Still active
Start Year 2018
 
Description ODDI Phenotypic drug discovery in Parkinson's 
Organisation University of Oxford
Department Alzheimer's Research UK Oxford Drug Discovery Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Collaborative drug discovery project in Parkinson's
Collaborator Contribution Collaborative drug discovery project in Parkinson's
Impact Ongoing
Start Year 2017
 
Description Oxford collaboration for molecular imaging (PET) in a rodent model of Parkinson's disease. 
Organisation University of Oxford
Department Department of Oncology
Country United Kingdom 
Sector Academic/University 
PI Contribution Richard Wade-Martins' lab has engineered rodent models of Parkinson's disease: LRRK2 BAC transgenic rats expressing human wild-type, G2019S, or R1441C LRRK2 mutations. These models have been extensively characterised using behavioural tests, voltammetry, electrophysiological recordings and immunohistochemistry analyses, showing that transgenic rats aged 18-21 months bearing any of the LRRK2 mutations exhibit L-DOPA responsive motor dysfunction, impaired striatal dopamine release, and cognitive deficits, but with no apparent neurodegeneration or protein accumulation on histology. In collaboration with the Imaging Core at the Oncology Department, we have optimised a scanning protocol for the aged rat-cohorts that will allow the acquisition of 18F-DOPA PET data to further characterise the effect of these mutations on dopamine metabolism, and validate these rodent models for future imaging studies. The aim is to provide early imaging readouts for the response to therapy with candidate compounds in an animal model of the early stages of PD.
Collaborator Contribution This collaboration allows us to bring new methods to OPDC. Our collaborators provide the radiotracers needed to perform our molecular imaging studies (fluorodopa is not routinely produced or distributed), and the facilities and expertise to run our scans. Veronique Gouverneur's lab has pioneered a new synthesis route for fluorodopa, and they are currently working to scale it up to production level for us. Sean Smart and Veerle Kersemans run the PET facility at the Oncology Department and have optimised the imaging logistics, and helped with acquisition protocols and data reconstruction so we are able to scan our aging cohorts in time.
Impact Initial pilot studies have been performed to detect and address imaging-specific problems before starting the analysis of the transgenic cohorts. The dose and injection timing of aromatic amino acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT) inhibitors (benserazide and entacapone respectively), have been optimised to avoid fluorodopa metabolism outside the brain. The dose of radiotracer and scanning timings are currently under investigation with further pilot scans. We will start imaging the transgenic cohorts at the beginning of 2018, and we anticipate to complete data acquisition and analysis by the end of the year. With the outputs generated from this research, we will be able to apply for further funding to advance our use of molecular imaging for model characterisation and, in the future, for studies evaluating promising candidate compounds to modify disease progression.
Start Year 2016
 
Description Oxford collaboration for molecular imaging (PET) in a rodent model of Parkinson's disease. 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Richard Wade-Martins' lab has engineered rodent models of Parkinson's disease: LRRK2 BAC transgenic rats expressing human wild-type, G2019S, or R1441C LRRK2 mutations. These models have been extensively characterised using behavioural tests, voltammetry, electrophysiological recordings and immunohistochemistry analyses, showing that transgenic rats aged 18-21 months bearing any of the LRRK2 mutations exhibit L-DOPA responsive motor dysfunction, impaired striatal dopamine release, and cognitive deficits, but with no apparent neurodegeneration or protein accumulation on histology. In collaboration with the Imaging Core at the Oncology Department, we have optimised a scanning protocol for the aged rat-cohorts that will allow the acquisition of 18F-DOPA PET data to further characterise the effect of these mutations on dopamine metabolism, and validate these rodent models for future imaging studies. The aim is to provide early imaging readouts for the response to therapy with candidate compounds in an animal model of the early stages of PD.
Collaborator Contribution This collaboration allows us to bring new methods to OPDC. Our collaborators provide the radiotracers needed to perform our molecular imaging studies (fluorodopa is not routinely produced or distributed), and the facilities and expertise to run our scans. Veronique Gouverneur's lab has pioneered a new synthesis route for fluorodopa, and they are currently working to scale it up to production level for us. Sean Smart and Veerle Kersemans run the PET facility at the Oncology Department and have optimised the imaging logistics, and helped with acquisition protocols and data reconstruction so we are able to scan our aging cohorts in time.
Impact Initial pilot studies have been performed to detect and address imaging-specific problems before starting the analysis of the transgenic cohorts. The dose and injection timing of aromatic amino acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT) inhibitors (benserazide and entacapone respectively), have been optimised to avoid fluorodopa metabolism outside the brain. The dose of radiotracer and scanning timings are currently under investigation with further pilot scans. We will start imaging the transgenic cohorts at the beginning of 2018, and we anticipate to complete data acquisition and analysis by the end of the year. With the outputs generated from this research, we will be able to apply for further funding to advance our use of molecular imaging for model characterisation and, in the future, for studies evaluating promising candidate compounds to modify disease progression.
Start Year 2016
 
Description PREVENT 7T 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Application of 7T technology to understand the effects of inherited risk of dementia
Collaborator Contribution Coordination of national PREVENT study of people at risk of dementia
Impact Pending
Start Year 2019
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PSP network 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution A new netwrok to coordinate clinical and genetic and imaging research of this severe neurodegenerative disorder
Collaborator Contribution 1. coordinated recruitment 2. biomarker development
Impact PPI acivities; Papers pending;
Start Year 2015
 
Description PSP network 
Organisation Progressive Supranuclear Palsy Association (PSPA)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution A new netwrok to coordinate clinical and genetic and imaging research of this severe neurodegenerative disorder
Collaborator Contribution 1. coordinated recruitment 2. biomarker development
Impact PPI acivities; Papers pending;
Start Year 2015
 
Description PSP network 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution A new netwrok to coordinate clinical and genetic and imaging research of this severe neurodegenerative disorder
Collaborator Contribution 1. coordinated recruitment 2. biomarker development
Impact PPI acivities; Papers pending;
Start Year 2015
 
Description PSP network 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution A new netwrok to coordinate clinical and genetic and imaging research of this severe neurodegenerative disorder
Collaborator Contribution 1. coordinated recruitment 2. biomarker development
Impact PPI acivities; Papers pending;
Start Year 2015
 
Description PSP network 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution A new netwrok to coordinate clinical and genetic and imaging research of this severe neurodegenerative disorder
Collaborator Contribution 1. coordinated recruitment 2. biomarker development
Impact PPI acivities; Papers pending;
Start Year 2015
 
Description R4VAD 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution A DPUK meeting Oxford in January 2016 RE: stem cells, models and human studies lead to applications to TSA/BHF/AS Vascular Dementia call resulting in the 3 funded projects, one of them being Human (R4VAD), with Prof Joana Wardlaw leading c£1.2M.
Collaborator Contribution Leadership on the project and academic expertise.
Impact Too early to report significant outputs or outcomes at present.
Start Year 2016
 
Description Rodent fMRI imaging 
Organisation ETH Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution OPDC provides mouse models of Parkinson's
Collaborator Contribution ETH carries out fMRI scanning on mice
Impact Ongoing project
Start Year 2016
 
Description SerCymru Fellowship 
Organisation Government of Wales
Country United Kingdom 
Sector Public 
PI Contribution Supervising a Research Fellow. Project title: Deconvoluting the dementia phenotype using functional genomics and computational approaches
Collaborator Contribution Funding the project
Impact This is a multidisciplinary collaboration between biological sciences and informatics/statistic. We have gained assess to EBI data resources which will be analyzed within the scope of the project.
Start Year 2017
 
Description Socio-economic variations in care home admission and health care utilisation in people with dementia living in Wale 
Organisation Swansea University
Department Swansea University Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution We have constructed a dementia cohort using Welsh routinely-collected healthcare data. We are providing our expertise and intellectual input on a study being run by researchers at the University of Liverpool on socioeconomic variations in care home admission for people with dementia.
Collaborator Contribution Swansea University - access to data, expertise, intellectual input University of Liverpool - project management, expertise, intellectual input
Impact No outputs or outcomes yet. Collaboration is multidisciplinary: medicine, data science, epidemiology
Start Year 2018
 
Description Socio-economic variations in care home admission and health care utilisation in people with dementia living in Wale 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution We have constructed a dementia cohort using Welsh routinely-collected healthcare data. We are providing our expertise and intellectual input on a study being run by researchers at the University of Liverpool on socioeconomic variations in care home admission for people with dementia.
Collaborator Contribution Swansea University - access to data, expertise, intellectual input University of Liverpool - project management, expertise, intellectual input
Impact No outputs or outcomes yet. Collaboration is multidisciplinary: medicine, data science, epidemiology
Start Year 2018
 
Description Stanford University 
Organisation Stanford University
Country United States 
Sector Academic/University 
PI Contribution generation of polygenic risk scores
Collaborator Contribution sharing genotyped data and PRS
Impact none yet
Start Year 2019
 
Description Structural and functional connectivity in the human basal ganglia in health and disease using high resolution MRI at 7T 
Organisation University of Oxford
Department Nuffield Department of Clinical Neurosciences
Country United Kingdom 
Sector Academic/University 
PI Contribution FMRIB scans and clinical data from our cohort